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OBJECTIVES OF THE STUDY:   
 This study tested the hypothesis that alcohol ingestion causes up-regulation of proteins involved in 
duodenal iron absorption, leading to iron overload.  
METHODS: 
Patients  with  alcoholic  cirrhosis  (AC)  (n  =  24)  were  the  subjects  of  the  study.  Such patients  
who  were  required  to  undergo  a  medically-indicated  upper  gastrointestinal endoscopy  were  
recruited  into  the  study  after  informed  consent.  Patients who underwent an endoscopy for 
investigation of dyspepsia and who were found to have no endoscopic abnormalities served as 
control subjects (n = 30). Duodenal mucosal and blood samples were obtained from the subjects. 
Duodenal tissue was used to determine mRNA  levels  of  divalent  metal  transporter  1  (DMT1)  and  
ferroportin,  both  of  which are  involved  in  non-heme  iron  absorption  in  the  duodenum. Blood 
was used for estimation of serum C-reactive protein (CRP), ferritin, iron, haematological parameters 
and tests of liver function.  Data were analyzed by student’s t-test and analysis of variance or 
Kruskall-Willis and Mann-Whitneys test, as appropriate. A p value of less than 0.05 was taken to 
indicate statistical significance.  
RESULTS: 
Patients  with  AC  had  significantly  lower  levels  of  haemoglobin  and  serum  iron  and higher 
levels  of  serum  CRP.  Other haematological and iron indices were not significantly altered. 
Parameters of liver function were deranged in these patients. Levels of mRNA for DMT1 and 
ferroportin in the duodenal mucosa of these patients tended to be  higher,  when  compared  with  
control  subjects;  however,  these  increases  were  not statistically significant.   
Gene  expression  of  DMT1  and  ferroportin  tended  to  be  higher  in  those  with  AC. However,  
these  results  need  confirmation  to  ascertain  whether  this  up-regulation  may contribute to the 
iron overload associated with alcoholic liver disease. 
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INTRODUCTION 
Iron is one of the physiologically important trace elements. The total amount of iron 
present in the body is in the range of 3-4 grams, of which around two-thirds is present 
in hemoglobin (Adamson, 2008). In the body, iron is present either as heme (attached 
to a porphyrin nucleus) or as iron-sulphur compounds. The largest consumer of iron in 
the body is the erythoid precursors in bone marrow (Cook et al; 1973). The rest is 
utilized by other cells for incorporation, as prosthetic groups, into proteins. In proteins, 
they may be either a structural component or a functional component. For example, 
they may form part of the active site of enzymes, of myoglobin (in muscle cells) and 
cytochromes involved in mitochondrial respiration and bio-transformation in the liver 
(Murray, 2009).  
 
During fetal development, iron stores are developed by materno-embryonic and 
materno-fetal transfer. Post-natally, iron is obtained from the diet by absorption in the 
duodenum. Transferrin takes up the iron absorbed and transports it in blood. Iron is 
delivered to tissues requiring iron, especially immature erythroid cells (Cook et al; 
1973).  The major contributor to serum iron is iron recycled from macrophages, which 
is approximately 20-30 fold more than the amount of intestinal iron absorbed 
(Andrews, 1999). Senescent RBCs are phagocytosed by macrophages, which degrade 
hemoglobin, releasing iron which returns into the circulation. Excess iron is stored in 
the hepatocytes and macrophages as ferritin.  Iron, once it enters the body, cannot be 
excreted either by the liver or kidney, as there is no regulated excretion of iron 
(Adamson, 2008). Iron is lost from the body only through exfoliation of skin and 
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mucosal cells, through faeces due to shedding of epithelial cells and through bleeding 
(Adamson, 2008). 
 
Regulation of iron metabolism is very important, as excess iron leads to free radical 
formation and progressive organ damage (Murray, 2009b).  Iron homeostasis in 
mammals involves complex regulation of transport, storage and utilization of iron 
(Hentze et al., 2004). 
 
ABSORPTION OF IRON 
Iron is indispensible for all living organisms. Organisms have to absorb iron from the 
diet and also maintain iron homeostasis in the body (Adamson, 2008).  
 
Heme and non-heme iron are absorbed from the intestinal lumen across the apical 
membrane of duodenal enterocytes. It is exported out across the basolateral membrane 
of the enterocytes and enters the portal blood.   
 
Iron deficiency can lead to anemia and growth arrest. Iron overload causes toxic free 
radical formation leading to progressive tissue damage (Adamson, 2008). Numerous 
evolutionally conserved physiological mechanisms have evolved for the maintenance 
of iron homeostasis. These are systems for environmental iron scavenging, and 
mechanisms for increasing iron solubility (Eisenstein, 2000). Dietary factors that 
increase iron solubility are ascorbic acid (which acts by reducing Fe3+ to Fe2+) 
(Greenbeeg, 1957) and substances which increase the gastric acid secretion (eg. 
alcohol), which helps keep non-heme iron in a reduced state   (Bezwoda et al, 1978; 
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Charlton, 1964). A diet rich in oxalates and phytates reduce the bioavailability of non-
heme iron (Adamson, 2008). 
 
SOURCES OF DIETARY IRON:  
The dietary forms of iron are of two types: heme and non-heme (Bjorn-Rasmussen et 
al., 1974). At physiological pH, non-heme iron is insoluble in aqueous solutions 
(Huggins, 2006). Dietary non-heme iron is mainly present as ferric iron (Fe3+) and as 
ferritin from plant sources. The major source of non-heme iron  are  plant sources, 
which includes dark green leafy vegetables, cereals, legumes, eggs and dried fruits. 
Iron from plant sources form weak complexes with phytates or tannins. This decreases 
their bio-availability (Adamson, 2008). Iron obtained from animal sources is mainly in 
the form of heme. Heme contains iron which forms a stable complex with a porphyrin 
nucleus (Kotani, 1969). Sources of heme iron are red meat, kidney, liver, pork, 
chicken and fish. The iron content in each type of food may vary, with highest 
amounts being present in red meat. Heme is well absorbed in the duodenum and is 
relatively unaffected by other food components (Lynch et al, 1985). Non-heme iron is 
much less bio-available compared to heme iron (McCance and Widdowson, 1942). 
Ferritin, though a non-heme iron form, is less influenced by other food components, as 
iron is locked inside a hetero-polymeric protein cage, thus preventing interaction with 
other dietary components (Theil, 2012). 
 
PROTEINS INVOLVED IN IRON ABSORPTION: 
Heme iron and non-heme iron absorption occurs via distinct pathways. The process of 
absorption of heme iron is not clearly understood.  A heme transporter (heme carrier 
protein 1[HCP-1]) has been identified on the apical membrane of enterocytes 
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(Shayeghi et al, 2005). Once heme enters the enterocyte via this transporter, it is 
degraded by the action of heme oxygenase; the iron released has a similar fate as that 
of non-heme iron (Raffin et al, 1974), as described below.  
 
Divalent metal transporter 1 (DMT1/SLC11A2/DCT1/Nramp2):   
DMT1 is a protein involved in iron import into the cytoplasm of cells. It is a highly 
conserved member of the family of membrane-bound divalent cation transporters or 
the natural resistance-associated macrophage protein (Nramp) (Cellier et al, 1995). 
DMT1 was first cloned from rodents (Gruenheid et al, 1995).  
 
Structure of divalent metal transporter 1: 
DMT1 has 561 amino acids and 12 transmembrane domains, with an extra-
cytoplasmic loop having 2 asparagine-linked glycosylation signals. It also has a 
membrane-targeting motif over the extracytoplasmic loop and a consensus transport 
motif, which is commonly present in other homologous cation transport proteins in 
other species. These transporters have a structure consisting of a conserved 
hydrophobic core encoding 10 highly conserved transmembrane segments with 
conserved intra- and extracytoplasmic loops. This evolutionary conservation proves 
the key role of these groups of proteins (Gunshin et al., 1997; Lee et al., 1998; Picard 
et al., 2000). 
 
Expression of divalent metal transporter 1 
DMT1 is expressed in all tissues. The tissues that abundantly express DMT1 are the 
duodenum, erythroid cells and liver. Kidney, brain, thymus, heart, lung and testis are 
other tissues that express DMT1 to a significant extent (Gunshin et al., 1997). In the 
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proximal duodenum, DMT1 is expressed by villous enterocytes but not by crypt cells 
(Canonne-Hergaux et al., 1999). It is expressed on the apical membrane of enterocytes 
but not in the lamina propria or goblet cells, in keeping with its role in luminal iron 
intake (Canonne-Hergaux et al, 1999).   
 
Function of divalent metal transporter 1 
DMT1 is a symporter. It transports ferrous iron and protons into the cell. It requires a 
low pH for its action (Gunshin et al, 1997). It acts as an apical transmembrane iron 
transporter in enterocytes and can transport reduced dietary non-heme iron into 
intestinal enterocytes (Gunshin, 1997). DMT1 is not specific for ferrous iron; it also 
transports a number of other divalent metals (Gunshin et al, 1997).  
 
Non-heme iron is present in the diet as insoluble ferric iron complexes. Ferric iron has 
to be reduced to the ferrous form as the intestinal iron transporter, DMT1, can 
transport only ferrous iron (Gunshin et al., 1997). 
 
Duodenal cytocrome b (dcytb): 
The brush border surface of the duodenal mucosa has inherent ferric reductase enzyme 
activity (Pountney et al., 1999), due to presence of a protein, dcytb, which converts 
Fe3+ to Fe2+ (Raja et al., 1992; Andrew et al., 2001).  
 
Structure of dcytb  
Dcytb was identified by subtractive cloning strategy. It has 286 amino acids and six 
transmembrane domains (McKie et al., 2001). The enzyme shares homology with 
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heme-containing cytochromes, especially cytochrome b561, which also has ferric 
reductase activity (Altschul et al., 1997).  
 
Expression of dcytb 
Dcytb is mainly expressed in duodenal brush border cells, thus suggesting its 
involvement in iron uptake. Its main location is in mature enterocytes in the duodenum 
(McKie et al., 2001). Mature enterocytes are present in the upper villus region. This 
region forms the part with highest iron absorption activity (O’Riordan et al., 1995). 
Dcytb is not expressed in the crypt region and other parts of small intestinal mucosa 
(McKie et al., 2001).   
 
It lacks an iron-responsive element in its mRNA sequence, which is important in the 
regulation of iron metabolism.  However, iron levels in the body regulate the 
expression of dcytb in the duodenum (McKie et al., 2001).    
 
No cases of dcytb mutations have been reported in humans. Genetic deletion studies in 
mice failed to show any major defects in iron absorption or utilization (Gunshin et al., 
2005). This is probably due to presence of other reducing substances in the intestine, 
like ascorbic acid or H+ ions.  
 
The Fe2+ entering the cell can undergo one of two fates, depending on intracellular 
requirement of enterocytes. It can either be stored in the enterocytes as ferritin, or can 
be transferred into plasma which is done with the help proteins ferroportin and 
Hephaestin present at the basolateral membrane (Pierre et al, 2002; Donovan et al, 
2005). 
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Ferroportin (FPN/ SLC40A1/ IREG1/MTP1):  
Ferroportin belongs to the metal transporter protein 1 family (Abboud and Haile, 2000; 
McKie et al., 2000).  
 
Structure of ferroportin 
Ferroportin has 581 amino acids and 10-12 transmembrane domains (Donovan et al., 
2005). Each transmembrane domain has a length of 18-12 residues, with the fourth 
domain being slightly longer. They have 12 cysteine residues with disulphide bonds 
within the lipid bilayer and on the surface (Devalia et al, 2002).  Ferroportin forms a 
functional dimer (De Domenico et al., 2010).  
 
Expression of ferroportin 
High expression of ferroportin is found in macrophages, duodenal mucosal cells, 
hepatocytes, Kupffer cells and placental syncytiotrophoblast cells (Abboud and Haile, 
2000). In the duodenum, ferroportin is expressed only in mature absorptive epithelial 
cells of villi and is present on the basolateral surface of enterocytes (Abboud and 
Haile, 2000). Ferroportin expression is low in most other cells, including erythriod 
cells. 
 
The gene for ferroportin is regulated by iron regulatory proteins (IRPs) that bind to 
iron-responsive elements(IRE) present on the 5’ untranslated region (UTR) of 
ferroportin mRNA (Sanchez , 2006).  
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Functions of ferroportin 
Ferroportin is a protein involved in efflux of ferrous iron (Fe2+) from cells. In the 
duodenum, due to its location on the basolateral membrane of enterocytes, it helps in 
efflux of iron from enterocytes in to blood (Murray, 2009).  
 
Ferroportin is also the receptor for hepcidin, an iron regulatory hormone (Nemeth et 
al., 2004). Hepcidin binds to ferroportin and stimulates its endocytosis and proteolysis 
in lysosomes (Nemeth et al., 2004). The mechanisms underlying the internalization 
and ubiquitination of ferroportin are not entirely elucidated. However, it is thought that 
hepcidin binds to the extracellular loop of ferroportin at amino acids 320-350, between 
the fifth and sixth loops (De Domenico et al., 2008b). Hepcidin binding to ferroportin 
leads to binding of the protein kinase, Janus kinase 2 (Jak2), to ferroportin. This causes 
auto-phosphorylation and activation of the bound Jak2. Activation of Jak2 results in 
the phosphorylation of two adjacent tyrosine residues in the cytosolic loop of 
ferroportin, resulting in internalization of the hepcidin-ferroportin complex (De 
Domenico et al, 2009). The net result is that release of iron from cells is inhibited. 
Evidence from various studies strongly suggests that the hepcidin-ferroportin axis is 
active in macrophages but the effect of hepcidin on ferroportin in duodenal enterocytes 
is less convincing (Yamaji et al., 2004; Chaston et al., 2008).  
 
Hephaestin (hp) 
Hephaestin is a membrane-bound protein on the basolateral surface of enterocytes in 
the small intestine. It has ferro-oxidase activity (Syed et al 2002; De Domenico et al., 
2007) and it plays a major role in intestinal iron absorption (Vulpe et al., 1999; Chen, 
2004). It is involved in iron efflux from enterocytes. It requires copper for its structural 
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and enzymatic activity (Vulpe et al., 1999; Syed et al 2002; Chen, 2004). Ferroportin 
favours the transport of only ferrous iron (Murray, 2009). Transferrin, required for 
transport of iron, can take up iron only in the ferric form. Hephaestin oxidizes ferrous 
iron into ferric iron. The ferric iron is then loaded on to transferrin and transported in 
circulation (Murray, 2009). The iron thus circulates bound to transferrin; tissues take 
up transferrin and utilize the iron (James and Jandl, 1963) 
Figure 1 show the processes involved in the absorption of iron (heme and non-heme) 
by duodenal enterocytes, its storage and transfer across the basolateral membrane.  
 
 
Figure 1: Processes involved in absorption of iron in the duodenum. 
(Adapted from Evstatiev and Gasche. Gut, 2012) 
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TRANSPORT OF IRON  
Transferrin and transferrin receptor 
Iron is transported in blood by transferrin. Normally, iron occupies 30% of the iron-
binding sites on transferrin (Adamson, 2008). 
 
Structure and localization: 
 Transferrin is a dimeric plasma glycoprotein of 80 kDa, synthesized by the liver 
(McPherson, 2009). It has a high affinity for Fe3+ and reversibly binds two atoms of 
Fe3+.  Each monomer of transferrin attaches to Fe3+ to form holo-transferrin. Levels in 
serum are inversely proportional to body iron status. Loaded transferrin circulates in 
the blood, delivering iron to various tissues that are in need of iron. It binds to 
transferrin receptors on the cell surface (Adamson, 2008). The transferrin receptor is 
an integral membrane protein of 90kDa (Aisen and Hu, 1978). It is a homodimer. Each 
monomer of transferrin receptor binds a single holo-transferrin (Adamson, 2008).  
Transferrin receptors are of types 1 and 2 - TfR1 and TfR2. TfR1 is involved in 
receptor- mediated uptake of iron by cells (Ponka et al., 1998). TfR2 can facilitate 
cellular iron uptake from holo-transferrin, but is not sufficient in absence of TfR1 
(Levy, 1999). TfR2 is homologous to TfR1 (Kawabata et al, 1999). It is mainly 
expressed in hepatocytes, duodenal crypt cells and erythroid cells (Kawabata et al, 
2001). TfR1expresssion is seen mainly in erythroid cells. It is up-regulated during 
erythroid development, while TfR2 is mainly expressed in liver and is up-regulated 
during liver development. This reflects different functions of the 2 types of tranferrin 
receptors (Kawabata et al, 2001). TfR1 is mainly involved in transferrin-mediated iron 
uptake into cells. TfR2 is mainly involved in regulation of iron metabolism (Kawabata 
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et al, 2001) by a HFE-mediated pathway involved in synthesis of hepcidin. The 
affinity of TfR2 for transferrin is 30 times lower than that of TfR1 (Kawabata et al, 
2000; West et al., 2000).  
 
Regulation of synthesis of transferrin receptors  
Cellular iron levels regulate the synthesis of transferrin receptors, by post-
transcriptional mechanisms. A high cellular demand for iron increases the transferrin 
receptor pool. Post-transcriptional control is mediated through binding of iron 
regulatory proteins (IRP) to iron-response elements (IRE) at the 3’ un-translated 
region of mRNA for TfR1. This binding of IRP to 3’ IRE stabilizes mRNA against 
degradation. TfR2 expression, in contrast to TfR1, is not regulated by IRE/IRP 
regulatory system (Kawabata et al, 1999).  
 
Studies have shown that knocking out transferrin and transferrin receptors resulted in 
severe neurological defects, due to iron deficiency during brain development. Severe 
iron deficiency was found in erythroid cells, leading to severe anaemia and death. 
Other tissues showed normal development, suggesting that these tissues might have 
mechanisms for iron uptake other than via transferrin receptors (Andrews and 
Schmidt, 2007).      
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IRON UPTAKE, STORAGE AND UTILIZATION  
Immature erythrocytes are major users of iron, using about a billion iron molecules per 
day for hemoglobin synthesis (Andrews Schmidt, 2007). Uptake occurs via transferrin 
receptor 1(TfR1). Holo-transferrin binds to TfR1. The complex is internalized by 
receptor-mediated endocytosis (Ponka et al.  1998). The internalized endosome 
complex is merged with a lysosome. The resultant acidic pH created inside the 
endosome reduces the affinity of the transferrin receptor for the iron-transferrin 
complex, leading to its disintegration (Sipe and Murphy, 1991), releasing transferrin 
and ferric iron into the lumen. The transferrin receptors return to the surface of the 
plasma membrane for re-use. STEAP 3 (six transmembrane epithelial antigen of the 
prostate 3), a protein present on the endosomal membrane, reduces the iron from Fe3+ 
to Fe2+ (Mc Kie et al 2005; Ohgami et al., 2005) the ferrous iron moves into the 
cytoplasm with the help of Nramp 2/DMT1, an endosomal membrane protein. Figure 
2 shows the process of transferrin uptake by cells.  The iron is utilized for various 
intracellular requirements. The ferritin present in the cells takes up the excess iron, 
thus storing the iron for future use (Higgins, 2006).  
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Figure 2: Transferrin cycle 
(Adapted from Mckie 2005 Nature Genetics) 
 
Ferritin:  
Ferritin was the second of all proteins to be crystallized in 1937 (Laufberger et al., 
1937). It is an iron storage protein. It is important in iron homeostasis. Free iron can 
generate reactive species with the potential to damage DNA and proteins (Higgins, 
2006). Thus, the intracellular iron pool has to be buffered; this process is critical for 
cell survival (Higgins, 2006).  
 
Expression and structure of ferritin  
Ferritin is ubiquitously expressed in the body and is found in cells and in serum 
(Higgins, 2006). It is highly conserved among a wide variety of species. Its cytosolic 
form in vertebrates forms heteropolymers consisting of 2 subunits, the heavy (H) 
subunit and the light (L) subunit (Higgins, 2006). L monomers have a molecular 
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weight of 18.5 kD with 174 amino acids, while H monomers have a molecular weight 
of 21kD with 182 amino acids.   Light and heavy ferritin subunits are homologous, but 
ferroxidase activity is present only in H-ferritin, which is essential for iron 
incorporation into the protein (Higgins, 2006). Figure 3 shows the structure of ferritin. 
The proportion of H and L subunits expression varies widely in different tissue. The L 
form predominates in liver and spleen, and H form predominates in heart and kidney 
(Higgins, 2006).  
 
Apoferritin forms a sphere with an internal space for ferric iron (stored as ferrihydrite 
mineral), to form holoferritin (Higgins, 2006). One apoferritin molecule has a 
molecular weight of 450kD. Twenty four subunits (maxiferritin), with H and L chains, 
assemble to form a hollow, symmetrical apoferritin shell (Higgins, 2006). Each shell 
can sequester 4500 iron atoms (Harrison, 1996). Mineralization of the shell reflects 
iron present in the cell; mineralization of the apoferritin shell is normally well below 
its maximum capacity. Normally, the average amount of iron per ferritin shell is 
between 1000 to 1500 iron atoms, but can also vary from 0 to 2500 iron atoms per 
shell (Harrison et al., 1974). In iron overload associated with hemosiderin, toxic levels 
of iron occur in cells, with average number of iron per ferritin shell being 3000-4000 
(Harrison et al., 1974). The extracellular form is present in serum and is used as an 
important clinical marker of iron status (Higgins, 2006). 
 
Function of ferritin 
Free iron is toxic in cells. Iron sequestration is the primary role of ferrritin.  It has 
ferrioxidase activity (Higgins, 2006). It converts Fe2+ to Fe3+ and helps in its 
internalization and sequestration in the ferritin mineral core (Higgins, 2006). The 
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ferroxidase catalytic subunit is the H subunit with multiple active sites in the interior 
(Higgins, 2006). Fe2+ substrates enter the protein cage from the cytoplasmic side.  The 
catalytic product, peroxidiferric intermediate, is released to the interior pore for 
nucleation (Pereira et al., 1998). The uniqueness of ferritin is that it is the only protein 
which acts on its substrate and also stores it (Munro, 1986).  
   
          
              Figure 3:   Structure of ferritin 
                (Adapted from Knovich, et al. Blood Rev. 2009) 
 
The main storage sites for iron in the body are liver parenchymal cells and 
macrophages (Higgins, 2006). Iron stored in hepatocytes is acquired either from 
transferrin or from non-transferrin bound iron (NTBI).  NTBI is particularly important 
in iron overload states (Andrews and Schmidt, 2007). If serum iron levels exceed 
transferrin-binding capacity, then iron is found as NTBI (Andrews and Schmidt, 
2007). Iron exist as low molecular weight complexes with citrate (as iron-citrate) or as 
a ternary complex as iron-citrate-acetate complex (Grootvel et al, 1989). Other tissues 
also can acquire NTBI by transferrin-independent pathways.  NTBI uptake is mainly 
thought to occur via L-type calcium channels (Oudit et al., 2003) and TRPC6 
(transient receptor potential canonical protein) (Mwanjewe and Grover, 2004). Liver is 
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exposed to NTBI more than other tissues, as the portal circulation misses first-pass 
metabolism (Andrews and Schmidt, 2007).  
 
IRON CYCLE 
 
Figure 4: Iron cycle in the body 
Adapted from Andrews: Blood, 2008. 
Serum iron is derived from two sources, intestinal absorption and iron recycling from 
macrophages. Recycling from macrophages contributes 20-30 times more iron than 
from intestinal absorption. Macrophages phagocytose senescent red blood cells (RBC) 
(Andrews, 1999). In phagolysosomes, the RBCs are lysed and the hemoglobin is 
released from these cells. The globin is degraded into individual amino acids. Heme is 
degraded into the porphyrin ring and Fe3+. The iron is reduced to Fe2+ form by STEAP 
3 present on the membrane of phagolysosomes. It is transferred into the cytoplasm via 
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the protein divalent metal transporter 1(DMT 1) (Gunshin et al, 1997, Ohgami et al, 
2005). Iron is then either stored as ferritin or utilized for cellular needs. Excess iron 
can be transferred to the plasma by the help of ferroportin present on the surface of 
macrophages. The Fe2+ form has to get oxidized to be loaded on to transferrin 
(Murray, 2009). This oxidization is effected by ceruloplasmin, a copper-containing 
protein, homologous to hephaestin (Murray, 2009). Iron in transferrin is taken up by 
the cells that need it; mainly immature erythrocytes (Higgins, 2006).The iron cycle is 
depicted in Figure 4 
 
REGULATION OF IRON METABOLISM 
Regulation of iron homeostasis in the body occurs at the level of the cell and also in 
the body as a whole. Cellular iron uptake is proportional to the number of transferrin 
receptors on the cell surface. Within the cell, the main player involved in regulation of 
the number of transferrin receptors is the IRP/IRE (iron regulatory proteins/ iron 
responsive element) system. This system senses cellular iron levels and plays a role in 
increasing or decreasing the number of transferrin receptors on the cell surface. It also 
plays a role in regulation of iron storage and absorption (Sanchez, 2006).  
 
Iron responsive element (IRE) and iron regulatory proteins (IRP)  
IRPs are iron-sensing proteins. In iron-depleted states, IRP binds to IRE, which is 
found in the un-translated region (UTR) of mRNAs of iron transport and storage 
proteins (Leibold and Munro, 1988). Iron-sulphur clusters are incorporated into IRP1, 
making it an iron sensor (Rouault et al, 1991). With 4Fe-4S cluster formations, IRP 
cannot bind to mRNA (Haile et al., 1989). This has dual effects, depending on the 
location of the IRE. Binding of IRP to IRE in the 5’ un-translated region (5’ UTR) of 
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mRNA for ferritin, ferroportin and aminolevulinate synthase (involved in heme 
synthesis) blocks initiation of translation (Sanchez, 2006). Five tandem IRE on the 
3’UTR of TfR1 mRNA bind to IRP, stabilizing the mRNA (by inhibiting nuclease 
digestion); this allows synthesis of TfR1 required for iron uptake in iron-depleted 
states (Rouault et al.,1992). Thus, this post-transcriptional regulation by cellular iron 
status controls expression of proteins involved in iron acquisition (TfR1 and DMT1), 
storage (ferritin), utilization (ALA synthase), and export (ferroportin). Thus, the 
IRP/IRE system acts as a sensor of cellular iron levels and regulate homeostatic 
mechanisms accordingly (Sanchez, 2006). Figure 5 depicts these processes.  
 
 
Figure 5: Regulation of synthesis of iron-related protein by iron. 
(Adapted from Molecular Biology of the Cell, 4th edition.  Alberts et al) 
 
Systemic iron regulation is mainly dependent on hepcidin. This is an anti-microbial 
peptide that was independently discovered from plasma ultra-filtrates and human urine 
(Krause et al, 2000; Park et al, 2001). It is a hormone involved in iron homeostasis 
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(Pigeon et al 2001, Nicholas et al 2001; Fleming and Sly 2001). It is a highly 
conserved peptide. It is synthesised by the liver and is encoded by the HAMP gene on 
chromosome 19q. It is synthesised as inactive pre-prohormone of 84 amino acids, 
containing a signalling peptide and as a prohormone with 60-amino acids (Park et al, 
2001). Furin, a prohormone convertase, cleaves the prohepcidin to generate hepcidin, 
which has 25 amino acids (Park et al, 2001). Hepcidin circulates in plasma and is 
filtered by the kidneys (Krause et al, 2000; Park et al, 2001).  
 
Structure of hepcidin 
Hepcidin contains 25 amino acids. It has eight cystiene residues with four disulphide 
cross-links and a beta hairpin structure (Park et al, 2001). It has a highly conserved N-
terminal arm, essential for the hormone activity. The only proved target for the action 
of this hormone is ferroportin, which is involved in iron transfer from cells into the 
plasma (Nemeth et al., 2004). Figure 6 shows the structure of hepcidin. 
 
                                      
                                                        
Figure 6: Structure of hepcidin 
(Adapted from Ganz T. Blood. 2003) 
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The role of hepcidin in iron metabolism was first suggested by Pigeon et al. (2001).  It 
is now known to be a negative regulator of serum iron levels. It acts by decreasing iron 
efflux out of cells. It does so by binding to ferroportin (Nemeth et al., 2004). The 
ferroportin-hepcidin complex is internalized, decreasing iron efflux from intestinal 
cells and the macrophages (Nemeth et al., 2004).  Hepcidin deficiency has been shown 
to result in increased levels of ferroportin in the cell membrane, leading to increased 
iron entry into the body and resultant iron overload (Nemeth et al., 2004).   Hepcidin 
causes internalization of ferroportin and thus reduced iron release from macrophages 
(Delaby et al., 2005). It restricts intestinal iron absorption (Laftah et al, 2004). 
Mutations in hepcidin cause iron-overload conditions (Nicolas et al, 2001). 
 
                                
Figure 7: Regulation of ferroportin expression by hepcidin 
(Adapted from Kushner Blood 2010) 
 
Regulation of hepcidin 
Hepcidin expression is regulated by several factors, such as the iron status of the body 
and inflammation. The main regulatory pathways for hepcidin synthesis involve bone 
morphogenic proteins (BMP) and TfR2.  BMP is a member of the transforming 
growth factor beta superfamily. Hemojuvelin, a BMP co-receptor, interacts with 
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BMP6 and with BMP receptors, types 1 and 2 (Xia et al., 2008). The formation of this 
complex triggers the SMAD signalling cascade, by phosphorylation and activation of 
SMAD 1, 5, and 8. The SMAD 1, 5, 8 complex combines with SMAD 4, which acts as 
a transcription factor for enhancing hepcidin transcription (Wang et al., 2005; Truksa 
et al, 2006). 
 
Transferrin receptor 2 (TfR2) is expressed 5 times more in the liver than TfR1. It acts 
as a regulator of hepcidin synthesis. HFE protein is a transmembrane protein on 
hepatocytes. TfR1 serves to sequester HFE, thus preventing its interaction with TfR2 
(Lebron et al., 1998). This decreases the transcription of hepcidin. In iron-replete 
states, holo-transferrin binds to TfR1. This displaces HFE. HFE now interacts with 
TfR2; leading to SMAD activation, increasing the transcription of hepcidin, leading to 
decreased serum iron levels (Schmidt et al 2008). IL6 is also involved in 
transcriptional activation of hepcidin (Nemeth et al, 2004a) by the STAT pathway 
(Wrighting et al, 2003). The pathways involved are depicted in Figure 8.  
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Figure 8: Regulation of hepcidin synthesis 
(Adapted from Knutson 2010) 
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THE PROBLEM OF ALCOHOLISM AND ITS ILL-EFFECTS ON SOCIETY 
AND HEALTH 
Alcohol has been a part of human culture since the beginning of recorded history 
(Rehm et al, 2009). It is the most socially accepted addictive drug in India and the 
world. Alcohol abuse and dependence causes social problems, such as domestic 
violence and loss of productivity in work places, as well as traffic accident-related 
injuries and chronic organ disorders (Ji, 2012).  
 
The liver is the organ most affected by alcohol, leading to alcoholic liver disease 
(ALD). ALD consists of a spectrum of pathological changes ranging from fatty liver 
and alcoholic hepatitis to cirrhosis (Schuckit, 2008). Alcoholism is a leading cause of 
cirrhosis in the world (Mailliard and Sorrell, 2008).  
 
The liver is the organ involved in biotransformation of toxic substances in the body. 
Oxidative stress and lipid peroxidation, resulting in cell injury, occur in the liver in 
response to iron and alcohol (Frierman et al, 1985; McCord, 1998). Alcohol is 
metabolised in the liver by alcohol dehydrogenase and cytochrome P4502E1 
(CYP2E1) (Schuckit, 2008). The hepatotoxicity of alcohol is due to alcohol-induced 
oxidative stress. Activation of CYP2E1, NADPH oxidase and changes in 
mitochondrial function have been reported to cause oxidative stress (Lu and 
Cederbaum, 2008;  Bardag-Gorce et al, 2006; Kessova and Cederbaum, 2003; 
Cederbaum, 2006). Previous studies have shown that, despite heavy consumption over 
longer time periods, only a small number of alcoholics actually develop liver disease 
(Friedman, 2012). This suggests that other factors may be involved in the process of 
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alcohol-mediated liver damage. One such possible factor is iron (Friedman et al., 
1980). 
 
Iron is a transition metal that takes part in the Fenton reaction, leading to free radical-
mediated injury. Derangements in iron homeostasis have been associated with 
alcoholism (Chapman et al, 1982; Irving et al, 1988). Changes in the iron status of 
alcoholic patients range from anemia to iron overload (Ioannou et al, 2004). The 
anemia seen in these patients is mainly due to poor nutrition and gastrointestinal 
bleeding (Kimber et al, 1965).  At the stage of cirrhosis, the functioning of the liver is 
compromised, leading to various complications, including bleeding tendencies. It has 
been shown that well-nourished alcoholics do not have iron deficiency or anemia. This 
suggests that alcoholism per se is not the cause for the anemia (Lindenbaum, 1969; 
Lindenbaum et al, 1980, Sheehy et al, 1960).  
 
Alcoholic beverages contain high contents of iron. Studies have shown high amounts 
of iron in wines all over the world (Charlton et al., 1964).  Alcoholic beverage 
consumption, even in small to moderate quantities, is associated with iron overload in 
liver, as evidenced by elevated indices of iron stores (Ioannou et al., 2004). Advanced 
alcoholism is one of the major causes of hepatic iron overload in the world (Irving et 
al, 1988).  Studies have shown that iron overload is more severe, with earlier onset, in 
hereditary hemochromatosis in alcoholics than in non-alcoholics (Fletcher et al, 2002). 
Higher mortality rates are associated with alcoholic cirrhosis in the presence of 
increased hepatic iron content, suggesting that iron has a role in exacerbating alcoholic 
liver disease (Ganne-Carrie et al., 2000; Harrison Findik et al., 2006). Whole body 
retention studies done in alcoholics have shown a two-fold increase in intestinal iron 
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absorption, suggested to be due to increases in intestinal permeability (Duane et al, 
1992). Alcohol has also been shown to induce the transfer of iron and endotoxins from 
the intestine into the circulation (Tamai et al., 2000). 
 
 Iron is stored in the liver, with the hepatocytes being the primary site of storage. 
Injury to hepatocytes leads to leakage of iron and results in increased serum iron levels 
(Harrison Findik et al., 2007). In alcoholic liver disease, iron deposition in the liver is 
seen in parenchymal cells and Kupffer cells. In mild ALD, iron deposition is more 
prominent in parenchymal cells than in reticuloendothelial cells (REC) in liver. The 
increase deposition of iron in these cells is due to increased uptake of iron from 
transferrin in circulation, thus triggering alcohol-mediated free radical injury leading 
to hepatocyte injury (Suzuki et al, 2002; Kohgo  et al, 2005). In severe ALD, iron 
deposits are more prominent in the REC, due to endotoxemia and over-production of 
inflammatory cytokines (Kohgo  et al, 2005). Studies in mouse models of ALD 
suggest that pro-inflammatory cytokines increase the iron content in Kupffer cells, 
thus activating transcription factor nuclear factor –kappa B (NF-kB) (Harrison-Findik 
et al., 2009). These effects were abolished after iron chelation (Harrison Findik et al., 
2007a).  
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EFFECT OF ALCOHOL ON IRON HOMEOSTASIS 
Studies suggest that beverages with high alcohol content increase iron absorption due 
to stimulation of hydrochloric acid production in the stomach (Charlton et al, 1964). 
Hepcidin synthesis in the liver has been reported to be down-regulated in ALD (Bridle 
et al, 2006; Harrison Findik et al., 2006). According to  a recent study on human 
subjects, liver hepcidin levels were significantly lower in alcoholics, when compared 
with non-alcoholic subjects, with the highest suppression of hepcidin mRNA seen in 
heavy drinkers (Costa-Matos  et al, 2012). 
This down-regulation of hepcidin was seen despite iron overload in these patients, 
suggesting that hepcidin was no longer sensitive to body iron levels. Normally, 
hepcidin protects the body against iron overload by inhibiting intestinal iron 
absorption and iron efflux from macrophages. Alcohol intake compromises the body’s 
defence against iron overload (Harrison Findik et al., 2007a). In vitro studies have 
shown that alcohol does not alter the expression of TfR1, ferritin, IRP1 and 2, 
suggesting that the effect of alcohol on hepcidin is a direct one and not an indirect one 
due to the altered iron status of the cell (Harrison Findik et al., 2006). 
 
A mechanism involved in alcohol-mediated hepcidin suppression is thought to involve 
induction of oxidative stress (Harrison Findik et al., 2007a). Antioxidants have been 
shown to reverse the effect of alcohol on hepcidin in the liver and DMT1and 
ferroportin expression in enterocytes (Harrison Findik et al., 2007a). This suggests a 
major role of oxidative stress in regulation of hepcidin synthesis. Reactive oxygen 
species are generated during metabolism of alcohol. C/EBPα (CCAAT/enhancer-
binding protein alpha) is a promoter of hepcidin mRNA (Courselaud et al., 2002). 
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Alcohol has been shown to down-regulate hepcidin promoter activity and the DNA-
binding activity of C/EBPα (Harrison Findik et al., 2006).  
 
Animal models of ALD have shown that down-regulation of hepcidin occurred in 
hepatocytes, with up-regulation of ferroportin and DMT1 in enterocytes and 
macrophages (Bridle et al, 2006; Harrison Findik et al., 2006). Significant suppression 
of hepcidin mRNA in liver by alcohol was seen in a study with human subjects (Costa-
Matos  et al, 2012).  
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HYPOTHESIS OF THE STUDY 
Alcoholic liver disease has been reported to be associated with liver iron 
overload. The hypothesis of this study is that alcohol ingestion results in 
increased expression of duodenal proteins involved in absorption of non-
heme iron and may contribute to the hepatic iron overload seen.   
 
AIM OF THE STUDY 
The aim of this study was to determine mRNA expression levels of duodenal 
proteins that are involved in absorption of non-heme iron, in patients with 
alcoholic cirrhosis. The proteins studied were divalent metal transporter1 
(DMT1) and ferroportin (FPN)
  
           
 
 
 
 
 
 
 
 
 
      MATERIALS AND METHODS
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         MATERIALS AND METHODS 
 
 a. EQUIPMENT USED  
1. Elix and Milli-Q ultrapure water systems (Millipore, USA)  
2. pH meter (Systronics, India)  
3. Tabletop centrifuge (MPW R 350, MPW Poland)  
4. Glass homogenizer with Teflon pestle (1 ml capacity) (Kimble-Kontes, 
USA)  
5. Horizontal gel electrophoresis system (Broviga, Balaji Scientific Services, 
Chennai)  
5. Gel documentation system (Alpha Innotech, USA)   
6. Real-time thermo cycler (Chromo4, Biorad, USA) 
 
           b. CHEMICALS AND REAGENTS USED  
1. Nucleopore RNA isolation kit (Genetix Biotech Asia Pvt Ltd. New Delhi, 
India). 
2. Diethyl pyrocarbonate (DEPC), ethidium bromide, ethylene diamine 
tetraacetic acid (EDTA), formamide, formaldehyde, bromophenol blue and 
sodium hydroxide were obtained from Sigma, India.  
3. Sodium acetate was obtained from Sisco Research Laboratories Pvt Ltd, 
Mumbai,   India.  
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4. Absolute alcohol was obtained from Hayman Ltd, England.  
5. Agarose was obtained from Genei, Bangalore, India.  
6. 3–morpholinopropane sulfonic acid (MOPS) was purchased from Fluka 
Biochemika, from Sigma, Taiwan.  
7. Reverse transcription core kit, SYBR Green PCR master mix kit and gene-
specific primers were obtained from Eurogentec, Belgium.  
All chemicals used were of analytical grade. 
 
c. MISCELLANEOUS CONSUMABLES USED 
1. Glass vacutainer blood collection tubes were obtained from BD Biosciences, 
Plymouth, UK.  
2. Cryovials were purchased from Axygen, India, microtubes from Tarsons, 
India and filter tips from Molecular Bio-Products, India.  
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d. SUBJECTS  
Patients diagnosed to have cirrhosis of alcoholic aetiology, who 
presented to the Department of Hepatology, Christian Medical College, 
Vellore, and who was required to undergo a medically-indicated upper 
gastrointestinal endoscopy as a part of their clinical management, were 
the subjects of the study. They were recruited into the study, after taking 
informed consent, if they fulfilled the following inclusion and exclusion 
criteria:   
Inclusion criteria  
1. Patients of both genders of ages between 30-65 yrs  
2. A history of intake of 20-30 gm (2 -3 standard drinks) of alcohol 
per day for 5 or more years  
3. Diagnosis of cirrhosis based on clinical and/or ultrasonographic 
evidence or those with  portal hypertension and compensated liver 
disease  
Exclusion criteria 
1. Not willing to take part in the study 
2. An international normalized ratio (INR) above 1.5  
3. Evidence of any other co-existent liver disease 
4. Evidence of viral infection as a cause of liver disease 
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Patients with dyspepsia presenting to the Department of Gastroenterology, 
Christian Medical College, Vellore, who had normal liver function tests and 
who were required to undergo a medically-indicated upper gastrointestinal 
endoscopy as a part of their clinical management, and in whom no 
abnormalities were found on endoscopy, were used as control subjects.  
 
The Institutional Review Board (IRB) of Christian Medical College, Vellore, 
India approved the study.  
 
INFORMED CONSENT  
Informed consent was sought from each subject before recruitment into the 
study. The investigator explained to the patient and his/her relatives what the 
study entailed and what was required of him/her. This was done in a language 
that the patient and his/her relatives understood well. They were provided with 
an information sheet as well. These sheets were made available in 5 different 
languages (Hindi, Bengali, English, Tamil and Telugu), to cover the languages 
most commonly spoken by patients who are seen at Christian Medical College, 
Vellore. After the explanation, patients were required to sign an informed 
consent form. They were recruited into the study only after these formalities 
were completed. A copy of the information sheet and consent form is included 
in Appendix I.  
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          PATIENT DATA  
A proforma was prepared to collect relevant patient data. This is included in 
Appendix II.  The investigator elicited relevant history from each patient. 
Socio-demographic details and clinical data for each patient were obtained 
from their hospital records.   
 
SAMPLE SIZE CALCULATION  
Sample size calculations have been done with alpha error set at 5% with 
power of the study at 80%. Based on the results obtained in a previous 
study (Barton et al, 2003), sample size  calculations were done and found 
to be 30 subjects in each arm of the study, ie 30 patients with alcoholic 
cirrhosis and 30 control subjects. 
 
            SAMPLE COLLECTION 
When undergoing the medically-indicated upper gastrointestinal endoscopy, a 
sample of mucosal tissue from the second part of duodenum was obtained from 
all patients who were recruited into the study. The tissue was immediately 
snap-frozen and transported to the laboratory in liquid nitrogen. A blood 
sample (about 3ml) was also collected from each patient. The blood sample 
was used to obtain serum, which was used to estimate levels of ferritin, iron 
and C-reactive protein (CRP).  
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ESTIMATION OF SERUM FERRITIN  
Serum ferritin was estimated by an automated chemiluminesence assay. 
Analyser: Siemens, ADVIA Centaur system Xpi, UK.  
            Principle of the method:  
The method used a two-site sandwich immunoassay, using direct 
chemiluminesence technology. Two antibodies were used in the assay. The 
first antibody was a polyclonal anti-ferritin goat antibody labelled with 
acridinium ester and the second was a monoclonal mouse anti-ferritin antibody, 
which was covalently coupled with paramagnetic particles. The amount of 
relative light units detected by the system was directly proportional to the 
ferritin values.  
 
ESTIMATION OF SERUM IRON  
Serum iron was estimated by a colorimetric assay from Roche, as per 
manufacturer’s instructions.  
Analyzer: Roche Modular P clinical chemistry autoanalyser, Germany. 
Principle of the method:  
 In acidic medium and in the presence of ascorbate, ferric (Fe3+) iron is 
dissociated from transferrin and converted to ferrous iron (Fe2+). Ferrous iron 
combines with ferrozine to give a magenta colored complex; the color is read at 
560nm. The intensity of the color is directly proportional to the iron 
concentration in the sample. 
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ESTIMATION OF C-REACTIVE PROTEIN (CRP)  
Serum CRP was estimated by an automated particle-enhanced immune-
nephelometry assay from Siemens, carried out as per manufacturer’s 
instructions. 
Analyzer: BN Prospec, Siemens GmbH, Marburg, Germany.  
Principle of the method:  
Polystyrene particles coated with human CRP-specific monoclonal antibodies 
were mixed with serum samples resulting in formation of aggregates. These 
aggregates scatter light. The intensity of scattered light is directly proportional 
to concentration of C-reactive protein present in the sample (Ledue and Rifai 
2003).  
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          ISOLATION OF TOTAL RNA  
Duodenal mucosal samples were used for isolation of total RNA. This was 
done using the Nucleo-pore RNA-Sure mini kit from Genetix Biotech Asia Pvt 
Ltd New Delhi, India.  
Contents of the RNAsure minikit 
Lysis buffer LBA1 
Wash buffer LBA2 
Wash buffer WBA3 
Desalting buffer DSB 
Reaction buffer for rDNase 
rDNase, RNase free water 
RNAsure sheredder column 
RNAsure mini column 
Collection tube (2ml) 
Collection tube (1.5ml) 
 
The following protocol was followed. All steps were carried out at room 
temperature. 
Step 1: 350μl of lysis buffer was added to each biopsy sample.  
 
 Step 2: The tissue was homogenized, using 60-65 strokes of a hand-held glass 
homogenizer.  
 
Step 3: 3.5μl beta-mercpatoethanol was added to the homogenized sample; the 
mixture was subjected to vortex mixing for 30 seconds 
 
Step 4:  A fresh RNA-Sure shredder column was placed in a 2ml collection 
tube provided by the manufacturer. The mixture obtained from step 3 was 
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added to the shredder column and was centrifuged at 11,000g for 1 minute. The 
filtrate obtained in the collection tube was transferred to a fresh 1.5ml 
centrifuge tube.  
 
Step 5: 350μl ethanol was added to the filtrate and mixed thoroughly by 
pipetting the fluid up and down.   
 
 Step 6: A fresh RNA-Sure mini-column, placed in a 2ml collection tube 
provided by the manufacturer, was taken. The mixture obtained from step 5 
was loaded on the column; the tube was centrifuged at 11,000g for 30 seconds. 
The filtrate in the collection tube was discarded and the mini-column was 
placed in a fresh 2 ml collection tube.  
 
Step 7:  350μl of desalting buffer provided in the kit was added to the mini-
column; the tube was centrifuged at 11,000g for 1 minute.  
 
Step 8:  Recombinant DNase (rDNase) reaction mixture was prepared by 
adding 10μl of reconstituted rDNase provided to 90μl of reaction buffer for 
rDNAase. 95μl of the DNase reaction mixture was added to the RNA-Sure 
mini-column and incubated at room temperature for 15 min. 
 
Step 9: Lysis Buffer 2 (LBA2) was added to the mini-column, which was then 
centrifuged for 30 second at 11,000g. The mini-column was transferred to a 
fresh centrifuge tube. 
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Step 10: 600μl of wash buffer (WBA3) was added to the mini-column and 
centrifuged for 30 seconds at 11,000g for 30 seconds. The filtrate obtained was 
discarded and the column transferred to a new collection tube. 
 
Step 11: 200μl of WBA3 was added to the mini-column and centrifuged at 
11,000g for 2-3 minutes. The mini column was now placed in a fresh 1.5ml 
nuclease-free collection tube.  
 
Step 12: 35-40 μl of RNase-free water was added to the column to elute the 
RNA by centrifuging at 11,000g for 1 minute. The elute obtained contained the 
isolated RNA,  
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ASSESSMENT OF INTEGRITY OF ISOLATED RNA BY GEL 
ELECTROPHORESIS 
The integrity of the RNA isolated was confirmed by agarose gel 
electrophoresis.   
Step 1: 0.5 M EDTA solution, pH 8, was prepared.   
  
            Step 2: 10X 3-(N-morpholino) propanesulfonic acid (MOPS) was prepared.  
For 100ml:  
Dissolved 4.186 gm of 0.2M MOPS in sterile DEPC-(0. 1%)-treated water.   
NaOH was used to adjust the pH of the solution to 7.  
Sodium acetate (0.6804 gm) (to obtain a final concentration of 50mM) and 2ml 
of 0.5M EDTA (to obtain a final concentration of 10nM) were added to the 
solution.   
 
Step 3: 1.2% agarose gel preparation 
To  34  ml  of  DEPC-treated water in  an  conical  flask, 0.48 gms  of  agarose  
was added. This was heated till the mixture boiled and the agarose melted.     
 
Step 4: To the melted agarose, 2.15ml of formaldehyde, 4 ml of 10X MOPS 
and 2µL ethidium bromide was added. The contents were mixed well. This 
mixture was poured into a gel casting tray, combs inserted and allowed to set 
for 1 hr.  
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Step 5: For sample preparation, 4µl of each RNA sample was mixed with 2µL 
of 10X MOPS, 3.5µl of formaldehyde and 10µL of formamide.   
 
Step 6: The sample mixture was incubated at 60oC in a dry bath for 15 
minutes.  
 
Step 7: The running buffer consisted of 40 ml of 10X MOPS and 360 ml of 
0.1% DEPC-treated water. This was poured into the electrophoresis tank. 
 
Step 8: The sample mixture, after incubation at 60oC, was mixed with 2µl 
bromophenol blue.   
 
Step 9: The cast gel was placed in the buffer tank and samples loaded into the 
wells in the gel.  
 
Step 10: The samples were electrophoresed for 45 min at 150 volts.   
 
Step 11: The RNA bands separated were visualized using an ultraviolet 
transilliminator in an Alpha Innotech Flourchem SP gel documentation system. 
Two distinct bands were seen, which represented the 28S and 18S ribosomal 
subunits of RNA. When the 2 bands in each sample were found in an 
approximate band density ratio of 2:1, this was considered as evidence of RNA 
of good quality.   
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RNA QUANTITATION:  
A nano-spectrophotometer was used to estimate RNA in the samples.  
Principle: Nucleic acids absorb strongly ultraviolet light at a wavelength of 
260nm. An  optical  density  reading  of  1.0  at  260  nm  was  taken  to  
indicate  an  RNA concentration of 40μg/ml. 
 
cDNA CONSTRUCTION BY REVERSE TRANSCRIPTION  
Reverse transcription of RNA was carried out using the core kit from 
Eurogentec. 
 Principle of the procedure:  
In the presence of dNTP, random nanomers and reaction buffer, the reverse 
transcriptase enzyme converts RNA into cDNA. . 
 
Step 1: Reagents in the reverse transcriptase core kit, except for the reverse 
transcriptase, were thawed by placing on ice pack in a clean biohazard hood. 
The reverse transcriptase was kept in the freezer till used.  
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Step 2: The RT reaction mixture consisted of:  
1µg of RNA and 10µL of a reaction mixture consisting of the following:   
Volume  Component  Final 
concentration 
1 μl 10X reaction buffer 1X 
2 μl  2.5 mM MgCl2 5 mM 
2 μl  dNTP 2.5 mM 500 μM each dNTP 
0.5 μl  Random nonamers 2.5μM 
0.2 μl  RNase inhibitors 0.4 U/μl 
0.25 μl  Reverse transcriptase 1.25 U/μl 
To make final volume up 
to 10μl. 
   RNase-free water  
1 μg    Template (total RNA)  
 
Step 3:  A master-mix was prepared by adding together all the above reagents, 
except the template and RNAse-free water, in the proportions specified. The 
master mix was constituted appropriately EACH TIME for the number of 
samples that required reverse transcription. 
 
Step 4: Required  amounts  of  RNAse-free  water  were  added  to  each  tube  
to  make  the reaction volume up to 10µL.   
 
Step 5:  RNA was added to individual tubes.  
 
Step 6: 5.95μl of the master mix was added to each reaction tube. 
 
Step 7: Negative control reactions were also set up. These were:  
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i) No reverse transcriptase (RT) tube:  This was a tube that contained all the 
above reagents except the reverse transcriptase. This negative control was used 
to confirm that there was no DNA contamination of the RNA sample used. 
 ii)  No RNA tube: This tube contained all the reagents except the template 
(RNA). This was to confirm that the reagents and consumables used were not 
contaminated with DNA.   
 
Step 8: All the reaction tubes were subjected to a short centrifugation in a 
microcentrifuge.   
 
Step 9: The reaction tubes were placed in a thermo-cycler (Chromo4, Bio-
Rad). 
 
Step 10: The thermo cycler was programmed as follows:  
Initiation step                        25oC for 10 min 
Reverse transcription step     48oC for 30 min 
RT enzyme inactivation        95oC for 5 min 
 
At the end of the reverse transcription, the cDNA obtained was stored at -20oC. 
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            REAL-TIME POLYMERASE CHAIN REACTIONS (PCR)   
The cDNA obtained was amplified by real-time PCR. The components for 
performing a single 20µL PCR reaction were as follows:  
 
Volume  Component 
2 μl cDNA template (the reaction mixture obtained at the end of 
reverse  transcription)  
10 μl   SYBR Green Mastermix 2X   
4 μl Gene-specific primers 
4 μl Autoclaved ultrapure water  
 
The PCR reactions were set up either in a 96-well plate format or in PCR tubes in 
strips. To ensure reproducibility all samples were assayed in duplicate.  
 
Gene-specific primers: 
Gene specific primers were used for the polymerase chain reaction assays. The 
ones used were from published literature and were as follows: 
 
Human DMT1 (IRE Form) (Theurl et al., 2006).  
Forward primer: 5’-TGCTGCTATCATTCCAACACTAAATT-3’  
Reverse primer: 5’-ATATAGCCTGGTTAAGAATCATGCA-3’  
 
Human ferroportin (Theurl et al., 2006)  
Forward primer: 5’-TGACCAGGGCGGGAGA-3’  
Reverse primer: 5’- GAGGTCAGGTAGTCGGCCAA -3’  
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Human beta-actin (Jacolot et al., 2008)  
Forward primer: 5’-GTGGGGCGCCCCAGGCACCA-3’  
Reverse primer: 5’-CTCCTTAATGTCACGCACGATTTC-3’  
  
The concentrations of primers, extension and annealing temperatures and times 
for each gene of interest used were standardized for all 3 genes studied. These are 
shown below: 
 
Primer Annealing 
temperature and 
time 
Extension 
temperature 
and time 
Concentration of 
forward and reverse 
primer 
β-Actin 63.1°C for 
 1 minute 
72°C  for  
1 minute 
F.P=300nM/L 
R.P=300nM/L 
DMT-1 61°C for  
20 seconds 
72°C for 
 40 seconds 
F.P=300nM/L 
R.P=300nM/L 
 
Ferroportin 55.3°C for 
 20 seconds 
72°C for  
40 seconds 
F.P=300nM/L 
R.P=300nM/L 
 
         MgCl2 concentration was optimized to 5mmol/L for all the genes studied.  
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        The Opticon Monitor software in the thermal cycler was programmed as given 
below:   
 
Step  Temperature Time 
1 Incubation 50oC 2 min 
2 Incubation 95o C 10 min 
3 Denaturation step 95oC 1 min 
4 Annealing step Temperature and time for each studied 
gene were optimized 
5 Extension step Temperature and time for each studied 
gene were optimized 
6 Reading was taken 
7 Step 3 onwards steps were repeated for 39 cycles more 
8 From 60 to 95oC Melting curve analysis was done, it was read at 
every 1oC. 
9 Within the thermocycler samples were cooled and maintained at 
4oC for 10 min. 
10 End 
 
The products obtained were stored at - 20oC. 
 
Standard curves were generated to validate the reaction conditions for each 
gene of interest. A serial dilution of the template cDNA for each gene was used 
for standard curve construction. 
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k. CALCULATION OF GENE EXPRESSION  
The cycle threshold (Ct) value was the outcome parameter obtained at the end 
of the PCR assays. 
 
The relative expression of the target gene was calculated in comparison to an 
internal reference gene, using cycle threshold (Ct) values. Controlling for 
errors using internal reference gene is commonly done in qRT-PCR assays. It is 
presumed that the internal reference gene does not change under disease 
conditions and can hence control for errors while performing qPCR. This 
minimizes variability between samples.  
 
Each target gene data was normalized relative to beta-actin, which was used as 
the internal reference gene. The Ct value of beta-actin for each sample was 
subtracted from that of the gene of interest (DMT1 and ferroportin). This value 
was referred to as the ∆Ct value. Relative fold-change in the gene of interest 
was determined using a comparative Ct method. The formula used for this was:  
 
Relative fold-change = 2^ - ∆Ct (Schmittgen and Livak 2008).  
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STATISTICAL ANALYSIS  
The Statistical Package for the Social Sciences (SPSS) software package, 
version 16, was used to analyze the data obtained. The one-sample 
Kolmogorov-Smirnov test was used to determine whether the parameters in the 
study were normally distributed. Student’s unpaired t test was used to compare 
the means of the two groups studied (control and ALD subjects). Patients with 
ALD were categorized into those with and without coagulopathy. Analysis of 
variance (ANOVA) was used to compare means of control patients and those 
with ALD, with coagulopathy and without coagulopathy. A post-hoc test with 
Bonferroni’s correction was used for pair-wise multiple comparisons. Data that 
were not normally distributed were analysed using Kruskal-Wallis and Mann-
Whitney tests.  A p-value of less than 0.05 was taken to indicate statistical 
significance.  
             All parameters in the study were found to be normally distributed except for 
serum CRP, ferritin, iron, SGOT and ESR.  
 
  
 
 
 
 
 
 
 
                       RESULTS
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I. DATA ON THE TOTAL NUMBER OF SUBJECTS RECRUITED 
a. CHARACTERISTICS OF SUBJECTS  
A total of 54 patients were recruited. These consisted of 30 control patients and 24 
diagnosed to have alcoholic liver disease (ALD). Data for all parameters were not 
available from the medical records for all the patients recruited. Only available data 
were analyzed. The number of patients for whom each set of data was available is 
indicated in the tables showing the results of this study.  
 
Table 1 shows relevant clinical characteristics of the 2 groups. All the patients 
recruited were males. The mean ages of patients in the 2 groups were similar. Only 
those with ALD had a history of long-term alcohol consumption. Of these, 88% 
showed signs of liver cell failure, 67% of them had evidence of coagulopathy, 12.5% 
had diabetes mellitus and 4.1% had hypertension. 
 
Table 1: Characteristics of subjects  
 
Characteristic Control patients Patients with 
ALD 
 
Number of subjects 30 24 
 
Males/females 30/0 24/0 
 
Mean age in years (+SD) 43.67 (8.4) 45.16 (7.6) 
 
Mean duration of alcohol use in years 
(+SD) 
0 18.11 (7.58) 
Signs of liver cell failure present (%) 0/30 21/24 (88%) 
 
Evidence of coagulopathy (%) 0/30 16/24 (67%) 
 
Coexistent conditions (diabetes mellitus or 
hypertension) (%) 
0/30 4/24 (16.6%) 
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b. PARAMETERS OF LIVER FUNCTION  
Serum bilirubin, SGOT and alkaline phosphatase levels were significantly higher and 
serum albumin levels significantly lower in patients with ALD, compared with control 
patients Table 2).  
 
Table 2: Parameters of liver function in the subjects 
 
Parameter Control patients Patients with ALD 
 
Total serum bilirubin (mg/dl ) (+SD) 
 
0.588 (0.261) 
 
(n = 18) 
2.256 (1.491)* 
 
(n = 23) 
SGOT  (IU/L ) (+SD) 26.47 (6.8) 
 
(n = 18) 
60.47 (36.32)* 
 
(n = 23) 
SGPT  (IU/L)(+SD) 28.70 (14.13) 
 
(n = 18) 
23.87 ( 11.28) 
 
(n = 23) 
ALP (IU/L ) (+SD) 78.64 (21.65) 
 
(n = 18) 
131.34 ( 54.82)* 
 
(n = 23) 
Serum total protein (gms/dl) (+SD) 7.44 (0.23) 
 
(n = 18) 
7.6 ( 0.87) 
 
(n = 23) 
Serum albumin (gms/dl ) (+SD) 4.5 (0.30) 
 
(n = 18) 
3.2 ( 0.71)* 
 
(n = 23) 
* indicates p = < 0.001 when compared with control data. 
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c. HAEMATOLOGICAL PARAMETERS  
Hemoglobin levels were significantly lower in patients with ALD, compared with 
control patients (Table 3). There were no significant differences in values of MCV and 
MCHC between the 2 groups. 
 
Table 3: Hematological parameters in the subjects 
 
Parameter Control patients Patients with ALD 
 
Hemoglobin (gms/dL) (+SD) 14.3 (0.90) 
 
(n =29) 
 
10.6 (2.2)* 
 
(n = 23) 
Mean corpuscular volume (MCV) (fL/cell) 
(+SD) 
88.8 (4.6) 
 
(n = 22) 
 
90(9.9) 
 
(n =20) 
Mean corpuscular hemoglobin 
concentration (MCHC) (pg/dL) (+SD) 
33.6 (1.5) 
 
(n = 11) 
 
33.8 (1.9) 
 
(n = 17) 
* indicates p < 0.001 when compared with control data. 
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d. PARAMETERS OF IRON STORES  
Serum iron levels were significantly lower in the ALD group, when compared with 
the control group. Serum ferritin values were higher but the increase was not 
statistically significant (Table 4). 
 
Table 4: Parameters of iron stores in subjects  
 
Parameter Control patients Patients with ALD 
Serum iron (μg/dl) (+SD) 106.67(85.53) 
 
(n =29) 
74.82(53.62)* 
 
(n = 22) 
 
Serum ferritin (μg/l) 
(+SD) 
140.59(122.18) 
 
(n =29) 
378.6(511.1) 
 
(n = 22) 
 
          * indicates p < 0.05 when compared with control data. 
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e. PARAMETERS OF HEMOSTATIC FUNCTION. 
Parameters of haemostatic function in patients with ALD are shown in Table 5.  
These values could not be compared with those in control patients as these tests had 
not been done for control patients. The reference range for PT is 10-13 seconds,  
that for APTT is 25-35 seconds and that for INR is 1(Lehmann and Henry, 2009).  
 
Table 5: Parameters of haemostatic function in the subjects 
 
Parameter Control 
patients 
Patients with 
ALD 
Prothrombin time (sec) (+SD) Not available 14.14 (1.99) 
 
    (n = 22) 
 
Activated tissue thromboplastin 
time (sec)(+SD) 
Not available 38.66 (5.43) 
 
    (n = 13) 
 
International normalized ratio 
(INR) (+SD) 
 
Not available 1.29 (0.196) 
 
    (n = 22) 
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       f. PARAMETERS OF INFLAMMATION  
Patients with ALD had significantly higher serum C-reactive protein levels.  ESR 
values and total WBC counts were not significantly different between the 2 
groups (Table 6).  
 
Table 6: Parameters of inflammation in subjects 
 
Parameter Control patients Patients with ALD 
CRP (mg/L) (+SD) 3.27(1.98) 
 (n =30) 
15.871(35.162)* 
(n =23) 
Total WBC count 
  (cells/cumm) (+SD) 
6000(1838) 
(n =2) 
7878.9(3415.6) 
(n =19) 
ESR (mm at 60 min) 14.07 (8.25) 
(n =15) 
41.8(41.65) 
 
(n =5) 
        * indicates p < 0.005 when compared with control data. 
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II. DATA ON THE SUB-CATEGORIES OF SUBJECTS RECRUITED  
Patients with ALD were categorized into two groups, based on the presence or absence 
of coagulopathy. Sixteen patients out of 24 were found to have coagulopathy, while 8 
did not have coagulopathy. 
 
a. CHARACTERISTICS OF SUBJECTS  
Patients with ALD who did not have coagulopathy were significantly older than those 
with coagulopathy. The mean durations of alcohol consumption were similar in both 
sub-groups. All patients with coagulopathy showed signs of liver cell failure, while 
such signs were seen only in 62.5% of those without coagulopathy. Diabetes mellitus 
were found to be present in 6.25% and 25% respectively in those with and without 
coagulopathy, while   hypertension was found to be in 12.5% of those without 
coagulopathy (Table 7). 
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Table 7: Characteristics of sub-categories of patients with ALD 
 
 
Characteristic 
 
Control patients 
 
Patients with ALD 
with coagulopathy 
 
Patients with ALD 
without 
coagulopathy 
Number of subjects 30 16 8 
Males/females 30/0 16/0 8/0 
Mean age in years 
(+SD) 
43.67 (8.4) 42.68 ( 5.6) 51.5 ( 7.3)* 
Mean duration of 
alcohol use in years 
(+SD) 
0 18.1 ( 8.7) 19.5 ( 7.5) 
Signs of liver cell 
failure present 
0/30 16/16 (100%) 5/8(62.5%) 
Evidence of 
coagulopathy 
0/30 16/16 (100%) 0/8 (0%) 
Coexistent 
conditions (diabetes 
mellitus or 
hypertension) 
0/30 1/16 (6.25%) 3/8 (37.5%) 
* indicates p = 0.02 when compared to controls patients 
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b. PARAMETERS OF LIVER FUNCTION IN SUB-CATEGORIES OF 
PATIENTS WITH ALD 
Serum bilirubin, SGOT and alkaline phosphatase levels were higher and serum 
albumin levels significantly lower in patients with ALD with and without 
coagulopathy, compared with control patients. There were no significant differences in 
values of SGPT and serum total protein among the groups. 
 
Table 8: Parameters of liver function in the subjects 
 
Parameter Control patients ALD with 
coagulopathy 
ALD without 
coagulopathy 
Total bilirubin 
(mg/dl) (+SD) 
0.59 ( 0.26) 
n = 18 
1.03(0.41)* 
n = 15 
2.91(1.5)# 
n = 8 
SGOT (IU/L) 
(+SD) 
26.47 ( 6.8) 
n = 18 
56.5 (51.3)* 
n = 15 
62.6 ( 27.3)# 
n = 8 
SGPT (IU/L) 
(+SD) 
28.70 ( 14.1) 
n = 18 
24.87 (15.16) 
n = 15 
22.86 ( 9.1) 
n = 8 
ALP (IU/L) (+SD) 78.64 ( 21.7) 
n = 18 
117.6(29.1)* 
n = 15 
138.66 ( 64.3) 
n = 8 
Serum total protein 
(gms/dl) (+SD) 
7.44 ( 0.23) 
n = 18 
7.71 ( 0.44) 
n = 15 
7.54 ( 1.04) 
n = 8 
Serum albumin 
(gms/dl) (+SD) 
4.5 ( 0.30) 
n = 18 
3.5 ( 0.69)* 
n =15 
3.1 ( 0.70)* 
n = 8 
* indicates p <0.001 when compared with control subjects, compared to controls, 
 # indicates p <0.05 when compared with those with patients with ALD and coagulopathy.   
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c. HAEMATOLOGICAL PARAMETERS IN SUB-CATEGORIES OF 
PATIENTS WITH ALD 
Hemoglobin levels were significantly lower in patients with ALD, irrespective of the 
presence or absence of coagulopathy, when compared with control patients. Those 
with coagulopathy had significantly lower levels when compared with levels in those 
without coagulopathy. There were no significant differences in values of MCV and 
MCHC between control subjects and ALD patients with and without coagulopathy 
(Table 9). 
 
Table 9: Hematological parameters in subjects 
 
Parameter Control 
patients 
Patients with 
ALD with 
coagulopathy 
Patients with 
ALD without 
coagulopathy 
Hemoglobin(g/dL) 
(+SD) 
14.3 (0.90) 
(n =29) 
8.41(5.13)* 
(n = 14) 
611.94(1.51)*# 
(n = 8) 
Mean corpuscular 
volume (MCV) (fL/cell) 
(+SD) 
88.8 (4.6) 
(n = 22) 
89.86(11.49) 
(n =13) 
0.38(5.66) 
(n = 6) 
Mean corpuscular 
hemoglobin 
concentration (MCHC) 
(pg/dL) (+SD) 
33.6 (1.5) 
(n = 11) 
23.23(16.21) 
(n = 11) 
33.6(1.38) 
(n = 5) 
* indicates p <0.001 when compared with control subjects, compared to controls, 
 # indicates p <0.05 when compared with those with patients with ALD and 
coagulopathy.   
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d. PARAMETERS OF IRON STORES IN SUB-CATEGORIES OF PATIENTS 
WITH ALD 
Serum iron levels tended to be lower and serum ferritin levels tended to be higher in 
those with ALD, irrespective of the presence or absence of coagulopathy, when 
compared with the control group; the differences seen were, however, not 
statistically significant (Table 10). 
 
   Table 10: Parameters of iron stores in subjects 
 
Parameter Control patients Patients with 
ALD with 
coagulopathy 
Patients with 
ALD without 
coagulopathy 
Serum iron 
(μg/dl) 
(+SD) 
106.67(85.5) 
(n =29) 
70.63(54.8) 
(n = 14) 
68.74(34.88) 
(n = 8) 
Serum ferritin 
(μg/l) (+SD) 
140.59(122.2) 
(n =29) 
143.78(184.6) 
(n = 14) 
354.75(263.6) 
(n = 8) 
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e. PARAMETERS OF HEMOSTATIC FUNCTION IN SUBJECTS 
Patients with ALD and coagulopathy had significantly higher values for prothrombin 
times and INR, when compared with those with ALD but no coagulopathy (Table 11).  
 
Table 11: Parameters of haemostatic function in the subjects 
 
Parameter Control 
patients 
Patients with 
ALD with 
coagulopathy 
Patients with 
ALD without 
coagulopathy 
Protrombin time  
(sec)(+SD) 
Not available 15.02(1.7) 
n = 15 
 
12.24(0.98)# 
n = 7 
Activated tissue 
thromboplastin 
time (sec)(+SD) 
Not available 39.26(5.5) 
n = 11 
35.35(5.3) 
n = 2 
International 
Nationalized 
Ratio(+SD) 
Not available 1.38(0.17) 
n = 15 
1.11(0.08)# 
n = 7 
        # indicates p <0.001 compared with those with ALD with coagulopathy 
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f. PARAMETERS OF INFLAMMATION IN SUBJECTS 
Patients with ALD and coagulopathy had significantly higher serum levels of C-
reactive protein when compared with control subjects. Values of ESR were higher in 
those with ALD and coagulopathy but the increase was not statistically significant 
(Table 12). 
Table 12: Parameters of inflammatory status in subjects 
Parameter Control 
patients 
Patients with 
ALD with 
coagulopathy 
Patients with 
ALD without 
coagulopathy 
  CRP 
(mg/L)(+SD) 
3.27(1.98) 
n =30 
10.35(8.23)* 
n =14 
26.92(61.34) 
n =7 
Total WBC        
count (cells/cumm) 
(+SD) 
6000(1838) 
n =2 
7946.3(2684) 
n =13 
7733.3(4966) 
n =6  
ESR (mm at 60 
min) 
14.07 (8.25) 
n =15 
49.25(44.07) 
n =4 
12 
n =1  
      * indicates p < 0.01 when compared with control data
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III. GENE EXPRESSION STUDIES 
a. Assessment of integrity of isolated RNA: 
RNA isolated from the duodenal mucosal samples was subjected to agarose gel 
electrophoresis. The presence of two distinct bands in the gels, corresponding to the 
28S and 18S ribosomal subunits of RNA, was taken to confirm the integrity of RNA 
obtained from each sample. Figure 1 shows the image of a representative gel in which 
RNA samples were electrophoresed. 
 
Figure 1 
                     
Figure 1: Image of agarose gel showing 18S and 28S subunits of RNA isolated 
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b. Optimization of PCR assays by standard curve generation and melting curve 
analysis for target genes 
After completion of PCR assays for each gene of interest, the log fluorescence data 
graph, melting curves and standard curves were obtained.  
 
Divalent metal transporter-1  
Log fluorescence data graph for DMT1 
Figure 2 shows the log fluorescence data graph for DMT-1. The average efficiency of 
the PCR assays for DMT-1 was found to be 1.8 to 2.05. An efficiency of 2 indicates 
100% efficiency. The mean (+ SD) for cycle threshold values for control samples was 
26.3 + 2.5 and that for ALD samples was 24.4 + 2.2 
 
Figure 2: Log fluorescence data graph for DMT-1. The graph shows the PCR cycle 
number on the x-axis and relative log fluorescence units on the Y axis. The interrupted 
line depicts the cycle threshold set at a point above baseline fluorescence. 
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b. Melting curve for DMT-1  
Figure 3 depicts the melting curve for DMT-1. The melting curve analysis showed the 
presence of single peak at 75-76oC, indicating a single amplified product.  
 
                                       
 
 
Figure 3: Melting curve for DMT-1. The graphical plot of the melting curve was 
taken after the PCR assay was completed using DMT-1 specific primers.  The 
presence of a single peak at 75-76oC indicates the generation of a single product 
during PCR. 
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c. Standard curve for DMT-1  
Figure 4 shows the standard curve generated for DMT-1.  
       
 
                              
       
 
Figure 4: Standard curve for DMT-1. The graph shows the log of the quantity of 
cDNA on the x-axis and cycle threshold value on the y-axis.  
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Ferroportin: 
a. Log fluorescence data graph for ferroportin 
Figure 5 shows the log fluorescence data graph for ferroportin. In the PCR for 
ferroportin the average efficiency was found to be 1.8 to 2.09. The mean (+ SD) cycle 
threshold value for control samples was 25 (+ 2.5) and that for ALD was (23 + 2.2). 
 
 
 
Figure 5: Log fluorescence data graph for ferroportin.  The graph shows the PCR 
cycle number on the x- axis and relative log fluorescence units on the Y axis. The 
interrupted line depicts the cycle threshold set at a point above baseline fluorescence. 
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b. Melting curve for ferroportin  
Figure 6 depicts the melting curve for ferroportin.  The melting curve analysis showed 
the presence of single peak at 79-80oC. 
 
                       
 
 
Figure 6:  Melting curve for ferroportin. The graphical plot of the melting curve was 
taken after PCR assay were completed using specific primers for ferroportin. The 
presence of a single peak at 79-80oC indicates the generation of a single product 
during the PCR 
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c. Standard curve for ferroportin 
Figure 7 shows the standard curve generated for ferroportin. 
 
                                       
 
 
Figure 7: Standard curve for DMT-1. The graph shows the log of the quantity of 
cDNA on the x-axis and cycle threshold value on the y-axis.  
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Beta-actin 
a. Log fluorescence data graph  
Figure 8 shows the log fluorescence data graph for beta-actin. In the PCR for beta-
actin, the average efficiency of was found to be 1.9 to 2.07. The mean cycle threshold 
value (+ SD) for control samples was 27.3 (+ 2.4) and that for the ALD samples was 
26 (+ 2.3).  
 
Figure 8:  Log fluorescence data graph for beta-actin. The graph shows the PCR cycle 
number on the x- axis and relative log fluorescence units on the Y axis. The 
interrupted line depicts the cycle threshold set at a point above baseline fluorescence. 
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b. Melting curve for beta-actin  
 
Figure 9 depicts the melting curve for beta-actin.  The melting curve analysis showed 
the presence of single peak at 75-76oC, indicating a single amplified product.  
 
                                        
 
 
Figure 9:  Melting curve for beta-actin. The graphical plot of the melting curve was 
taken after PCR assay were completed using specific primers for beta-actin. The 
presence of a single peak at 79-80oC indicates the generation of a single product 
during the PCR 
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c. Standard curve for beta-actin 
Figure 10 shows the standard curve for beta-actin. 
                                          
 
 
 
 
Figure 10: Standard curve for beta-actin. The graph the log of the quantity of cDNA 
on the x-axis and cycle threshold value on the y-axis  
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c. Gene expression of DMT1 and ferroportin in duodenal mucosa of subjects  
 Gene expression levels of duodenal DMT-1 in control and ALD subjects 
Figure 11 shows mRNA expression levels of DMT1 in the control and ALD subjects. 
DMT-1 expression levels were higher in the ALD subjects when compared with the 
control subjects. However, the increase was not statistically significant (p = 0.08).  
 
 
Figure 11: DMT1 mRNA expression levels in control and ALD subjects. Data are 
shown as mean (± SD).The mean for control subjects is 3.8 (± 4.2) and that for ALD 
subjects was 6.9 (± 8.5). 
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 Figure 12 shows mRNA expression levels of DMT1 in those with ALD, with and 
without coagulopathy. DMT-1 expression levels were higher in those with ALD 
irrespective of the presence or absence of coagulopathy, when compared with control 
subjects. The increases seen were, however, not statistically significant. 
 
 
 
Figure 12: DMT1 mRNA expression levels in control and ALD patients, with and 
without coagulopathy. The mean (±SD) for control subjects was 3.8 (±4.3), that for 
subjects with ALD with coagulopathy was 7.7 (± 9.3) and that for subjects with 
ALD without coagulopathy was 5.6 (± 7.3) 
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Gene expression levels of duodenal ferroportin in control and ALD subjects 
Figure 13 shows mRNA expression levels of ferroportin in the groups studied. 
Ferroportin expression levels were higher in the ALD group when compared with 
the control group, but the increase was not statistically significant (p value =0.15).  
 
 
Figure13: Ferroportin mRNA expression levels in subjects in the control and ALD 
groups. Data are shown as mean (± SD) in each group. The mean (± SD) for the 
control subjects was 4.9 (± 2.7) and that for the ALD subjects was 6.6 (± 5.3).  
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 Figure 14 shows mRNA expression levels of ferroportin in the sub-groups of those 
with ALD. Expression levels were higher in subjects in both sub-groups of ALD, 
when compared with the control group, but the increases were not statistically 
significant. Expression levels in the 2 sub-groups of patients with ALD were similar. 
 
 
Figure 14: Ferroportin mRNA levels in subjects in the control and ALD groups, with 
and without coagulopathy. Data are shown as mean (± SD).The mean value for the 
control subjects was 4.9 (± 2.7), while that for subjects with ALD and coagulopathy 
was 7.1 (± 5.7) and for those with ALD without coagulopathy was 5.7 (± 4.5).  
  
 
 
               
 
 
 
                   DISCUSSION 
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DISCUSSION 
The past two decades have brought a huge amount of understanding to our knowledge 
in the field of iron biology. The mechanisms involved in iron absorption, metabolism 
in the body, regulation of these processes and its associations with numerous diseases 
were brought to light during this period. Studies done, have involved those on cells in 
culture, transgenic animal models and human subjects.   
 
The present study was done to determine mRNA expression levels of duodenal 
proteins involved in absorption of non-heme iron in subjects with alcoholic liver 
disease. The hypothesis of the study was that these proteins may be up- regulated in 
patients with alcoholic liver disease, thus increasing iron absorption and resulting in 
iron overload in the body. This hypothesis arose from the studies that have shown the 
existence of iron overload in patients with alcoholic liver disease (Powell, 2008; 
Harrison-Findik et al., 2006).  
 
Cirrhosis is a serious complication of excessive alcohol use. However, it has been 
shown that despite heavy alcohol consumption for long periods only a small 
percentage of such users progressed from alcoholic hepatitis to cirrhosis (Friedman, 
2012). This suggests that alcohol is not the only factor involved in the development of 
alcoholic cirrhosis (Friedman, 2012).  
 
Iron overload is often associated with alcoholism. Even moderate consumption of 
alcohol is associated with increased iron stores as indicated by elevations in serum 
ferritin (Milman and Kirchhoff, 2006), transferrin saturation (Chapman et al., 1982; 
Ioannou et al., 2004), iron levels in hepatocytes (Ioannou et al., 2004), TfR1 
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expression levels in hepatocytes (Suzuki et al., 2002) and intestinal iron absorption 
(Duane et al., 1992). Patients with genetic hemochromatosis (GHH), who consume 
excessive amounts of alcohol, have been shown to be more likely to develop severe 
liver disease and ultimately cirrhosis (Fletcher et al., 2002). The effects of alcohol and 
iron overload seen appeared to be synergistic. Both alcohol and iron are individually 
involved in induction of oxidative stress.  Previous animal studies have shown that 
alcohol consumption causes induction of the enzyme CYP2E1, which is involved in 
metabolism of alcohol (Murray, 2008). This in turn causes oxidative stress, which is 
known to down-regulate CEBP alpha, a promoter of hepcidin. This, in turn, results in 
down-regulation of hepcidin. Hepcidin down-regulates proteins involved in intestinal 
absorption of non-heme iron. It binds to ferroportin on the basolateral surface of 
enterocytes, leading to its internalization and degradation (Harrison Findik et al., 2006; 
Bridle et al., 2006). This event eventually results in degradation of DMT1 (Harrison 
Findik et al., 2006). Low levels of hepcidin, thus, cause up-regulation of proteins 
involved in intestinal iron absorption, leading to increased uptake of iron and resultant 
hepatic iron overload. These observations are from animal studies; such a sequence of 
events has not been reported in humans. Costa-Matos et al (2012) have shown that 
hepatic hepcidin expression in patients with alcoholic liver disease (without cirrhosis) 
is lowered; this correlated with the amount of alcohol consumed. In addition, they 
have reported increased serum ferritin and transferrin saturation levels in these 
patients. It has also been shown that there is a differential effect of hepcidin on 
macrophages and enterocytes, with the internalization and degradation of ferroportin 
by hepcidin shown to be more effective in macrophages (Yamaji et al., 2004; Chaston 
et al., 2008). 
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In the present study, liver function tests were deranged in patients with alcoholic liver 
disease (ALD). These patients had significantly lower hemoglobin levels than the 
control patients. In patients with coagulopathy, previous episodes of bleeding that have 
occurred may account for the anemia; the cause is less evident in those without 
coagulopathy. Values for MCV and MCHC in those with ALD were not significantly 
different from control patients, suggesting normal iron stores in the body in those with 
ALD. Ideally, it would be best to determine the iron content in the liver in these 
patients ascertain whether an iron load had developed in response to alcohol 
consumption. However, it was not possible to do so because it was not ethically 
possible to obtain a sample of liver for this. Because of this, surrogate marker of iron 
stores, such as serum iron and ferritin, were utilized. Serum ferritin in these patients 
was higher than in control subjects; however, this increase was not statistically 
significant. Serum ferritin levels are often used as an indicator of body iron stores; 
however, it is also an acute phase reactant and its levels are elevated in inflammatory 
states (Recon, 2012). Patients with ALD had significantly higher levels of CRP than 
control subjects, indicating the presence of systemic inflammation. Regression 
analysis showed no correlation between the ferritin and CRP, suggesting that increased 
serum ferritin may not be due to inflammation. In view of this, it would be difficult to 
conclude what the iron stores in the body were in these patients. Judging by the data 
on MCV, MCHC and ferritin, iron stores appear to be normal or may be elevated. Use 
of markers such as soluble transferrin receptor (Ferguson et al. 1992) or soluble 
haemojuvelin, which are now considered to be better indicators of iron stores (Lin et 
al., 2005; Zhang et al., 2007; Brasse-Lagnel et al., 2010) may be necessary to make the 
situation clearer. It was not possible to estimate these parameters in the present study 
due financial constraints.  
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In the present study, DMT1 and ferroportin mRNA expression tended to be higher in 
those with ALD when compared with control subjects; the increases were, however, 
not statistically significant (p value =0.08 for DMT1 and 0.1 for ferroportin). A larger 
number of samples will need to be studied to confirm these results. It would also be 
useful to estimate serum hepcidin levels in these patients and correlate this parameter 
with expression levels of duodenal proteins. However, it was not possible to do this in 
the present study, once again due to financial constraints involved.  
 
As far as it is possible to determine, this is the first study of its kind in patients with 
ALD. Harrison -Findik et al (2006) have reported up-regulation of DMT1 and 
ferroportin expression in duodenal enterocytes in animal models with alcohol liver 
disease. No reports of a similar nature done on humans have been found in published 
literature. Hence this study provides preliminary data on possible dysregulation in iron 
homeostasis in patients with ALD.  
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CONCLUSION 
The mRNA expression levels for proteins involved in absorption of non-heme iron in 
the duodenum showed a tendency towards up-regulation of DMT1 (apical iron 
transporter) and ferroportin (basolateral iron transporter). 
  
 
 
 
 
 
 
 
LIMITATIONS OF THE STUDY  
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LIMITATIONS OF THE STUDY 
 The sample size for the study was small. A larger number of patients will need 
to be studied to confirm the results.  
 Due to financial constraints, it was not possible to estimate serum levels of 
soluble transferrin receptor and soluble haemojuvelin as indicators of body iron 
stores. Similarly, it was not possible to estimate serum hepcidin levels. These 
parameters would have contributed to determining the true iron status of the 
patients in the study.
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FUTURE DIRECTIONS 
Further studies that are required for further studies on iron overload in alcoholic liver 
disease include:  
 estimation of levels of serum hepcidin and soluble transferrin receptor and 
soluble haemojuvelin  
 determination of expression levels of other duodenal proteins involved in iron 
absorption such as dcytb, hephaestin, transferrin receptor 1,ferritin and iron 
regulatory protein.  
 estimation of iron content in the liver  
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PATIENT INFORMATION SHEET FOR REQUEST FOR SAMPLE OF 
DUDENAL MUCOSA AND BLOOD 
As a part of the investigation of your current medical problem, the doctor taking care 
of you has advised you to undergo an endoscopy, during which a tube will be passed 
into your stomach and small intestine, so that the doctor can see whether there is any 
problem in these organs. During the procedure, the doctor will take a small piece of 
tissue from the stomach or intestine, so that certain tests can be done with this tissue 
in order to find out more about your illness. 
 
The Department of Biochemistry, in association with Department of Gastroenterology, 
is carrying out a study on all patients who undergo such an endoscopy to understand 
changes in the way iron is handled in the body in the patients who have liver disease, 
produced by intake of alcohol. Iron levels in the liver are often higher than normal in 
this situation. It sometimes worsens the disease. We do not know fully why this 
happens. We would like to study this problem to understand it better. In order to do 
this, we need to have a very small biopsy from the small intestine. This will be taken at 
the same time that the doctor looks at the inside of your stomach and intestine. We 
request your permission to take this piece of tissue. You will not feel any extra 
discomfort on account of this. We also request permission to take a sample of blood 
from you. This is to help us study what happens to iron in the blood.  
 
The samples that we request will be used purely for scientific research. Any remaining 
sample will be discarded. The collection of 3ml of blood will not cause any harm to 
your health in any foreseeable manner. All your personal information obtained by us 
from you will be kept confidential. 
The biopsy and blood samples that we request will be used purely for scientific 
research. The taking of these biopsy samples will not cause any harm to your health in 
any foreseeable manner. All your personal information obtained by us from you will 
be kept confidential. 
You may not benefit directly from the study. However, if you are willing to allow us 
to take these samples, it will help us try to understand why iron collects in liver in 
those who drink alcohol. This knowledge may help improve treatment for the disease. 
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However, if you do not wish to be part of this study, you are free to refuse give 
permission for this. The treatment you continue to receive in this hospital will be 
exactly the same whether you choose to be part of this study or not. 
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INFORMED CONSENT DOCUMENT FOR SAMPLES OF BLOOD AND 
DUODENAL BIOPSY SAMPLES 
The investigator has explained to me the details of the study proposed and what it 
involves. I have understood what has been said, including the following: 
1. A very small sample of tissue from my gut will be taken by the doctor at the 
time of my endoscopic procedure, which my treating doctor has advised me to have. 
1. It will not create any additional difficulty for my undergoing the procedure.  
2. A sample of blood (3 ml) will also be collected from me. 
3. Taking these samples will not affect my health in any foreseeable manner.  
4. The samples will be used to study what happens to the processes by which iron 
is handled by blood cells in patients who have liver disease due to alcohol intake. They 
will be used only for research purposes. 
 
 I am willing to donate the tissue and blood samples voluntarily and without any 
coerction from the investigators of this project. 
 
 
 
Signature of the donor:                                                                      Signature of the 
investigator: 
 
Name of the donor:   
 
 
Signature of the witness: 
 
Date  
 
Contact information of the investigator: Dr. Kavita Rasalkar. Ph.no. 9047495314 
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Patient information 
Controls  
Sl 
no  
 
Name  
 
Age 
 
Sex   
 
Diagnosis 
 
Bleeding 
history 
 
Bleeding 
tendency  
 
Hb  
 
MCV 
 
MCHC 
1 
Ujjal        37 M PUD 
N N 
15.4 87.5 NA 
2 
Shibshambu   39 M PUD 
N N 
14 88.6 NA 
3 
SantoshDeb   41 M PUD 
N N 
14.8 91 31 
4 
Ilangovan    33 M PUD 
N N 
15.7 NA NA 
5 
Bajrang      63 M PUD 
N N 
14.5 NA NA 
6 
SwapanKumar  56 M PUD 
N N 
12.7 98.6 34.2 
7 
MilanKanti   57 M PUD 
N N 
14.7 86 30.7 
8 
ToneyMathews 48 M PUD 
N N 
13.7 91 34.2 
9 
Anindya      31 M PUD 
N N 
14.5 88.8 35.3 
10 
Ashutosh     43 M PUD 
N N 
14.8 82.9 35.3 
11 
Minhazuddin  38 M PUD 
N N 
14.3 82.4 33.4 
12 
PannerSelvam 35 M PUD 
N N 
15.6 NA NA 
13 
Sahadat      29 M PUD 
N N 
14.3 80.7 33.2 
14 
RamPado      51 M PUD 
N N 
13 89.8 34 
15 
Bimalendu    51 M PUD 
N N 
NA NA NA 
16 
Babu         35 M PUD 
N N 
16.2 89.2 NA 
17 
SwapanDey    35 M PUD 
N N 
14 87.8 NA 
18 
Shivaiah     43 M PUD 
N N 
13.6 NA NA 
19 
Srimoujum    46 M PUD 
N N 
14.5 88.9 NA 
20 
Mahindra     41 M PUD 
N N 
15.7 94.3 34.6 
21 
Pramanik     58 M PUD 
N N 
13.3 NA NA 
22 
JamilPaiker  35 M PUD 
N N 
14.3 88.1 NA 
23 
DilipKumar   49 M PUD 
N N 
14.8 93.8 NA 
24 
Manohar      48 M PUD 
N N 
13.4 NA NA 
Note: M –Male, N –No, NA –Not available 
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25 
ArunBagath   48 M PUD 
N N 
13.2 83 NA 
26 
SamirHaldar  40 M PUD 
N N 
13.7 97.5 33.4 
27 
SanjayPandit 47 M PUD 
N N 
15.1 91.7 NA 
28 
TarunKumar   40 M PUD 
N N 
13.3 85.5 NA 
29 
Parameshwar  47 M PUD 
N N 
15 NA NA 
30 
KhalidIqbal  46 M PUD 
N N 
13.7 86.5 NA 
 
Mean 43.67    
  
14.3 88.8 33.6 
Note: M –Male, N –No, NA –Not available, PUD –Peptic ulcer disease 
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ALD patients  
Sl 
no 
 
Name 
  
Age 
 
Gender  
 
Diagnosis 
 
Bleeding 
history 
 
Bleeding 
tendency 
 
Hb 
 
MCV 
 
MCHC 
1 
Debabratha   50 M ALD N N 8.7 87.5 NA 
2 
Margabandhu  53 M  ALD            N N 12.4 88.6 NA 
3 
Rajendran    47 M ALD N Y 10.4 91 31 
4 
PronobBose   49 M ALD N Y 6.4 NA NA 
5 
LuxmiTudu    47 M ALD N N 11.7 NA NA 
6 
SajalMondol  42 M ALD N Y 6.9 100.4 33.4 
7 
Gunashekaran 53 M ALD N N 12.1 NA NA 
8 
DeepakKumar  46 M ALD N N 13.6 88.9 34.4 
9 
Ilango       45 M ALD N N 11.2 65.4 34 
10 
GopalPrasad  45 M ALD Y Y 10.1 91.4 32.9 
11 
Shankar          36 M ALD 
              
N Y NA 
  
104.9 36.5 
12 
UnniMoin     46 M ALD N Y 11 86.5 NA 
13 
HaridasNaik  43 M ALD N Y 11.2 91.3 34 
14 
Janardhan    39 M ALD N N 12.3 NA NA 
15 
Sridhar      46 M ALD Y N 8.6 87.5 33.5 
16 
MehatiAli    42 M ALD Y Y NA NA NA 
17 
RajeshPasi   36 M ALD N Y 7.5 96 33.1 
18 
santoshMonda 59 M ALD Y N 13 99.6 35.4 
19 
Durai        33 M ALD Y Y 8.8 87.9 NA 
20 
Shambunath   64 M ALD Y N 12.8 85.2 28.9 
21 
Yuvaraj      41 M ALD N Y 11.8 NA NA 
22 
Anuraj       49 M ALD Y Y 8.4 78.3 34.4 
23 
Venkatesan   50 M ALD N Y 14.1 88.6 35.7 
24 
Raja         34 M ALD Y Y 9.2 96.9 34.7 
 
Mean 45.16     10.6 90 33.8 
Note: M-Male, N –No, Y -Yes NA –Not available, ALD- Alcoholic liver disease, 
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Sl no  
 
Name  
 
Serum 
iron 
 
Serum 
ferritin 
 
PT 
 
INR  
 
APTT 
 
Total 
count 
 
ESR 
 
CRP 
1 
Ujjal        149 105 NA NA NA NA 10 2.97 
2 
Shibshambu   118 144 NA NA NA NA NA 2.97 
3 
SantoshDeb   63.3 68 NA NA NA NA 7 2.97 
4 
Ilangovan    92 46 NA NA NA NA 3 2 
5 
Bajrang      94 86 NA NA NA NA NA 1.05 
6 
SwapanKumar  55 118 NA NA NA NA 13 3.41 
7 
MilanKanti   113 115 NA NA NA NA 8 0.8 
8 
ToneyMathews 117 263 NA NA NA NA 20 2.97 
9 
Anindya      101 48.1 NA NA NA NA NA 2.97 
10 
Ashutosh     75.2 103 NA NA NA NA  2.97 
11 
Minhazuddin  81 438 NA NA NA NA 10 5.65 
12 
PannerSelvam 89 83 NA NA NA NA NA 3.34 
13 
Sahadat      77 71.7 NA NA NA NA 6 2.97 
14 
RamPado      105 42.8 NA NA NA NA 22 0.53 
15 
Bimalendu    59 246 NA NA NA NA NA 2.97 
16 
Babu         194 268 NA NA NA NA 8 2.97 
17 
SwapanDey      NA NA NA NA 20 NA 
18 
Shivaiah     43 38.4 NA NA NA NA NA 5.16 
19 
Srimoujum    91 510 NA NA NA NA 15 2.97 
20 
Mahindra     120 180 NA NA NA NA NA 2.97 
21 
Pramanik     28 365 NA NA NA NA NA 10.6 
22 
JamilPaiker  43 117 NA NA NA NA 35 7.3 
23 
DilipKumar   89 83 NA NA NA NA NA 3.34 
24 
Manohar      108 61.8 NA NA NA NA NA 2.97 
NA –Not available 
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25 
ArunBagath   55 71 NA NA NA NA NA 2.97 
26 
SamirHaldar  54 46.5 10.3 NA 27.6 NA NA 0.22 
27 
SanjayPandit 117 121 NA NA NA NA 20 2.97 
28 
TarunKumar   104 29.9 NA NA NA NA NA 2.97 
29 
Parameshwar  510 136 NA NA NA NA NA 3.45 
30 
KhalidIqbal  149 72 NA NA NA NA 14 3.45 
 
Means  106 140 NA NA NA 6000 14.07 3.27 
NA –Not available 
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Sl 
no  
 
Name  
 
Serum 
iron 
 
Serum 
ferritin 
 
PT 
 
INR 
 
APTT 
 
Total 
count 
 
ESR 
 
CRP 
1 Debabratha   52 54 NA NA NA 6400 12 3.34 
2 Margabandhu  34 175 10.1 0.94 NA NA NA NA 
3 Rajendran    97 184 14.1 1.29 37.8 7200 NA 2.97 
4 PronobBose   15 10.4 14.6 1.33 35.3 7000 NA 2.97 
5 LuxmiTudu    49 51.9 11.8 1.07 43.4 8600 95 15.1 
6 SajalMondol  195 1075.9 17.3 1.62 40.5 7800 NA 2.97 
7 Gunashekaran 92 23.6 12.7 1.19 39.1 5200 NA 2.97 
8 DeepakKumar  25 1167 12.7 1.15 31.6 16700 NA 166 
9 Ilango       39 31.4 13.7 1.14 NA NA NA 20.8 
10 GopalPrasad  36 1650 12.9 1.17 NA 3900 NA 2.97 
11 Shankar      22 15.5 NA NA NA NA NA NA 
12 UnniMoin     130 258 17.2 1.58 38.8 5000 11 10.1 
13 HaridasNaik   62.3 14.4 1.32 34.2 6000 NA 3.34 
14 Janardhan    52 17.3 14.4 1.32 NA 5000 NA 2.95 
15 Sridhar      27 45.4 14 1.32 52.8 13000 12 18.2 
16 MehatiAli    115 60.7 12.3 1.07 NA NA NA 5.26 
17 RajeshPasi   89 1525 16.4 1.5 40.2 10,200 NA 12.7 
18 santoshMonda 194 503.5 12.8 1.17 NA 10200 NA 4.9 
19 Durai        NA NA 18 1.65 39.3 11200 NA NA 
20 Shambunath   80 77.3 12.2 1.11 NA 4000 NA 2.97 
21 Yuvaraj      138 569.9 15 1.38 NA NA NA 2.97 
22 Anuraj       16 141 13 1.19 NA 6400 79 21.8 
23 Venkatesan   100 900 15.4 1.52 37.4 11100 NA 24.1 
24 Raja         49 267 16 1.47 32.2 NA NA 3.9 
 Mean  74.82 378.6 14.14 1.29 38.66 7878 41.8 15.8 
110 
 
NA –Not available 
Sl no  
Name  
 
TB 
 
AST 
 
ALT 
 
ALP 
 
Total 
protein 
 
Albumin  
1 
Ujjal        NA NA NA NA 7.5 3.9 
2 
Shibshambu   NA NA NA NA 7.5 4.3 
3 
SantoshDeb   0.5 27 21 92 7.2 4.7 
4 
Ilangovan    NA NA NA NA NA NA 
5 
Bajrang      0.4 23 18 74 NA NA 
6 
SwapanKumar  0.8 32 18 77 NA NA 
7 
MilanKanti   0.4 35 42 114 NA NA 
8 
ToneyMathews 0.4 27 32 78 NA NA 
9 
Anindya      1.3 16 12 67 NA NA 
10 
Ashutosh     0.8 35 59 79 NA NA 
11 
Minhazuddin  0.9 22 33 17 NA NA 
12 
PannerSelvam NA NA NA NA NA NA 
13 
Sahadat      0.4 25 28 76 NA NA 
14 
RamPado      0.4 26 30 94 NA NA 
15 
Bimalendu    NA NA NA NA NA NA 
16 
Babu         NA NA NA NA 7 4.5 
17 
SwapanDey    NA NA NA NA 7.3 4.6 
18 
Shivaiah     NA NA NA NA NA NA 
19 
Srimoujum    0.4 36 56 68 NA NA 
20 
Mahindra     0.6 19 13 75 NA NA 
21 
Pramanik     NA NA NA NA NA NA 
22 
JamilPaiker  0.5 24 27 97 7.7 4.6 
23 
DilipKumar   NA NA NA NA 7.6 4.6 
24 
Manohar      0.4 13 11 54 7.7 4.7 
NA –Not available 
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25 
ArunBagath   NA NA NA NA NA NA 
26 
SamirHaldar  0.4 30 18 101 NA NA 
25 
ArunBagath   NA NA NA NA NA NA 
26 
SamirHaldar  0.4 30 18 101 NA NA 
27 
SanjayPandit 0.5 35 34 96 7.5 5 
28 
TarunKumar   NA NA NA NA NA NA 
29 
Parameshwar  NA NA NA NA NA NA 
30 
KhalidIqbal  0.9 25 36 78 NA NA 
 
Mean  0.588 26.4 28.70 78.64 7.4 4.5 
NA –Not available 
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Sl 
no  
 
Name  
 
TB 
 
AST 
 
ALT 
 
ALP 
 
Total 
protein 
 
Albumin  
1 Debabratha   0.8 32 11 105 7.1 2.5 
2 Margabandhu  0.5 18 16 126 8.2 3.4 
3 Rajendran    1.1 54 37 141 8.7 3.5 
4 PronobBose   2.5 59 18 152 7.1 3 
5 LuxmiTudu    1.3 156 32 152 8.1 3.6 
6 SajalMondol  4.9 54 44 89 6.4 3.2 
7 Gunashekaran 1.3 38 18 134 7.2 3.7 
8 DeepakKumar  1.4 32 24 101 8.2 3.6 
9 Ilango       0.7 19 10 62 7.5 4.5 
10 GopalPrasad  1.5 38 16 90 7 3.4 
11 Shankar      NA NA NA NA NA NA 
12 UnniMoin     4.4 72 25 271 6 2 
13 HaridasNaik  1.2 41 23 112 8.1 3.2 
14 Janardhan    1.6 27 14 105 7.8 4.5 
15 Sridhar      4.1 86 16 136 6.5 3.2 
16 MehatiAli    2 17 17 86 7.9 4.5 
17 RajeshPasi   4.5 117 31 158 9 2.3 
18 santoshMonda 1.6 118 56 147 7.5 2.8 
19 Durai        3.5 84 12 67 6.9 3.2 
20 Shambunath   0.7 39 32 114 7.9 4.4 
21 Yuvaraj      2 53 22 65 7.2 3.1 
22 Anuraj       1.7 81 31 236 9.2 2.8 
23 Venkatesan   5.3 99 19 240 8.8 3.1 
24 Raja         3.3 57 18 132 6.5 2.2 
 Mean  2.25 60.47 23.87 131.34 7.6 3.2 
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NA –Not available 
 
The valves of DMT1 and Ferroportin expression were normalized to that of Beta-actin (arbitrary units) 
Sl no  
Name  
 
DMT1 expression 
levels 
 
Ferroportin 
expression levels 
1 
Ujjal        0.423373 1.853176 
2 
Shibshambu   1.094294 2.042024 
3 
SantoshDeb   1.693491 4.958831 
4 
Ilangovan    3.482202 5.938094 
5 
Bajrang      4.993322 5.502167 
6 
SwapanKumar  0.650671 3.758091 
7 
MilanKanti   9.447941 10.05611 
8 
ToneyMathews 0.946058 9.849155 
9 
Anindya      4.377175 6.32033 
10 
Ashutosh     0.373712 2.479415 
11 
Minhazuddin  5.656854 5.540438 
12 
PannerSelvam 10.41073 4.594793 
13 
Sahadat      3.605002 5.278032 
14 
RamPado      0.76313 11.63178 
15 
Bimalendu    0.353553 4.027822 
16 
Babu         10.41073 6.105037 
17 
SwapanDey    0.757858 5.028053 
18 
Shivaiah     12.38052 7.568461 
19 
Srimoujum    2.361985 3.386981 
20 
Mahindra     0.795536 2.12874 
21 
Pramanik     3.630077 5.540438 
22 
JamilPaiker  0.366021 1.474269 
23 
DilipKumar   0.858565 2.948538 
24 
Manohar      2.928171 7.260153 
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25 
ArunBagath   2.20381 1.453973 
26 
SamirHaldar  10.55606 5.35171 
27 
SanjayPandit 2.969047 3.317278 
28 
TarunKumar   15.67072 10.12605 
29 
Parameshwar  0.535887 1.717131 
30 
KhalidIqbal  0.650671 2.531513 
 
Mean  3.844906 4.992286 
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Sl no  
Name  
DMT1 expression 
levels 
Ferroportin 
expression levels 
1 
Debabratha   2.281527 6.727171 
2 
Margabandhu  1.394744 4.69134 
3 
Rajendran    0.737135 1.802501 
4 
PronobBose   20.82147 10.62949 
5 
LuxmiTudu    12.81712 1.892115 
6 
SajalMondol  6.105037 2.948538 
7 
Gunashekaran 19.97329 14.92853 
8 
DeepakKumar  0.493116 1.414214 
9 
Ilango       34.5353 21.70567 
10 
GopalPrasad  0.435275 1.79005 
11 
Shankar      1.558329 4.789915 
12 
UnniMoin     0.594604 3.434262 
13 
HaridasNaik  6.964405 15.34823 
14 
Janardhan    10.19649 12.295 
15 
Sridhar      8.339726 11.55143 
16 
MehatiAli    7.260153 8.514961 
17 
RajeshPasi   0.316439 1.717131 
18 
santoshMonda 0.293209 1.464086 
19 
Durai        12.90627 8.633826 
20 
Shambunath   12.81712 6.453134 
21 
Yuvaraj      1.22264 2.989698 
22 
Anuraj       1.802501 4.789915 
23 
Venkatesan   3.271608 3.655326 
24 
Raja         0.456916 5.205367 
 
Mean  6.983101                      6.640496 
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